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Abstract
Platelet-derived Growth Factor Receptor Beta Activates Abl2 through Direct
Binding and Phosphorylation
Kuanlin Wu
2021

The catalytic activity of Abl family kinases is tightly regulated in cells by a
complex set of intra- and intermolecular interactions and post-translational
modifications. Abl family kinases are activated by diverse cellular stimuli,
including receptor tyrosine kinase signaling. For example, the platelet-derived
growth factor receptor beta (PDGFRβ) is a potent activator of Abl family kinases.
However, the molecular mechanism by which PDGFRβ engages and activates
Abl family kinases is not known. We find that the Abl2 Src Homology 2 (SH2)
domain directly binds to phospho–tyrosine Y771 in the PDGFRβ cytoplasmic
domain. PDGFRβ directly phosphorylates Abl2 N-terminal half on multiple novel
sites including Y116, Y139 and Y161 within the SH3 domain, and Y299, Y303
and Y310 on the kinase domain. Y116, Y161, Y272 and Y310 are all located at
or near the SH3/SH2-kinase linker interface, which helps maintain Abl family
kinases in an auto-inhibited conformation. We found that PDGFRβ-mediated
phosphorylation of Abl2 in vitro activates Abl2 kinase activity, but mutation of
these four tyrosine (Y116, Y161, Y272 and Y310) to phenylalanine abrogated
PDGFRβ-mediated activation of Abl2. These findings reveal how the PDGFRβ
engages and phosphorylates Abl2 and how this leads to activation of the kinase,
providing a framework to understand how growth factor receptors engage and
activate Abl family kinases. Finally, the biological importance of PDGFR-

mediated activation on Abl2 is unclear. Our lab recently showed that Abl2 directly
binds and phosphorylates the integrin β1 cytoplasmic tail. Here, I provide initial
findings suggesting that PDGFR-mediated activation on Abl2 promotes Abl2integrin β1 interaction and β1 phosphorylation by Abl2. This process also inhibits
talin-integrin interaction. Since talin is the most important integrin activator, Abl2
may regulate talin-integrin interaction, and potentially acts as an integrin
inactivator. Abl2 acting downstream of PDGFR to regulate integrin activation may
provide a mechanism to allow PDGFR to crosstalk with integrin to regulate many
processes including cancer metastasis, angiogenesis and embryonic
development.
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CHAPTER 1- A MECHANISTIC OVERVIEW OF ABL
FAMILY NON-RECEPTOR TYROSINE KINASE.

Introduction
The Abelson (ABL) family of nonreceptor tyrosine kinases, comprised of Abl1
and Abl2 in vertebrates, translate diverse extracellular signals to regulate cell
proliferation, survival, migration and invasion. Abl1 was first identified as an
oncogene for the development of leukemia induced by Abelson murine leukemia
virus (A-MuLV) or chromosome translocation that results in expression of the
Bcr-Abl1 fusion protein (1-3). In addition to leukemia, recent studies have
demonstrated Abl family kinase’s role in solid tumor development (4-7),
neurodegenerative disease (8,9) and microbial pathogenesis (10-12).
Understanding how Abl kinases are regulated and what signaling pathways they
modulate is crucial in developing therapies for these diseases.
The catalytic activity of Abl family kinases is important in promoting actin-based
cell edge protrusion, facilitating endocytosis and phagocytosis, mediating DNA
damage responses, and regulating cell survival and proliferation in a variety of
cell contexts. These processes play essential roles in the development and
function of the cardiovascular, brain, and immune systems, among others (1223). This chapter will focus on the molecular mechanism of Abl family kinase
activation and regulation.

1

Conserved structural organization and cellular distribution of
Abl family kinases

Abl kinases have been identified in all metazoans. Vertebrates express two
closely related paralogs, Abl1 and Abl2, with highly conserved SH3-SH2-Kinase
cassette domain structure (Fig 1.1) (24,25). There are two major isoforms of both
Abl1 and Abl2 including the non myristoylated isoform 1a, and the myristoylated
isoform 1b. The N-terminal SH3-SH2-kinase domains of Ab1 and Abl2 share
over 90% sequence identity (Fig1.1) (26). Although Src kinase has a domain
organization similar to the N terminal half of Abl family kinases, they only share
52% identity in their kinase domains, and 37% in their SH3 and SH2 domains
(Fig1.1) (27). Abl1 and Abl2 have overlapping function in particular cellular
contexts, but possess unique roles due to their distinct C-terminal half domain
structure. For example, Abl1 tends to localize to the nucleus as it has a DNAbinding domain, three nuclear localization signals and a nuclear export signal in
its C-terminal half (24,28). On the other hand, Abl2 tends to localize at the cell
periphery, which is enriched with cell cytoskeleton, due to its microtubule and
actin binding domain in its C-terminus (Fig1.1) (29-31). Recent studies in our lab
show Abl2 not only binds growing microtubules and promotes microtubule
polymerization and stability, but also recruited to actin waves through
cytoskeletal interactions (30,31).
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Figure 1.1 Domain Organization of Abl family kinases
Domain organization and sequence comparison of Abl1, Abl2 and Src. Abl1, Abl2
and Src share high sequence similarity in the N-terminal half SH3-SH2SH1(Tyrosine Kinase) cassette. Abl1 and Abl2 each possess a unique C-terminal
domain composition, resulting in different cellular localization and function. Abl1
and Abl2 both have PxxP motifs (yellow strips). Abl1 has nuclear localization
sequences (NLS, gray stripes), a DNA-binding region (DNA, magenta) and a
nuclear export sequence (NES, light-blue stripe). Additionally, Abl1 has G-actin
(G, orange) and F-actin (F, purple)-binding domains. Abl2 has two F-actinbinding domains and two microtubule binding domains (MT, gray). Figure
adapted from (25).

The SH3 domain
SH3 domain binds to proline-rich peptide with a P-X-X-P consensus motif (P is
proline and X is any amino acid), which adopts polyproline type II helical
3

conformation to mediate both intermolecular and intramolecular interactions (3236). Interestingly, the crystal structure of Abl1 SH3 domain with bound ligand
was the first SH3 domain structure revealing how SH3 domain mediate proteinprotein interaction (36). It has since been reported that many PXXP containing
proteins are able to bind and regulate Abl family kinases (37).
The SH2 domain
SH2 domain bind to phosphotyrosine-containing peptides with sequence
specificity. Different SH2 domains have different preferences regarding the three
to six amino acid residues downstream from the phosphorylated tyrosine (38,39).
The Abl family kinase SH2 domain binds preferentially to the consensus
sequence of pY-X-X-P/L (pY is phosphotyrosine) (40,41). Our lab had shown that
Ab1 and Abl2 SH2 domains have significantly different (over 10-fold) binding
affinities for cortactin, mediated through a two-residue difference in their SH2
domain sequence (42). Abl family kinases SH2 domain had been reported to
bind to many different proteins These interactions play important role in
modulating Abl kinase activity (37,43,44).
The kinase domain
Abl family kinases are tyrosine kinase that specifically catalyze the transfer of
phosphate group from ATP on to the side chain hydroxyl of tyrosine residue.
Protein kinases play important role in signal transduction because
phosphorylation of target proteins can modulate their function in many different
ways. For example, phosphorated tyrosine residues in different receptors serve
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as docking sites to recruit multiple SH2 domain-containing signaling proteins (as
discussed above for SH2 domain interaction). Abl family kinase activity is also
regulated by different phosphorylation events (details of kinase regulation will be
discussed in next section) (45-47). Besides autophosphorylation, Abl family
kinases have been reported to phosphorylated many different substrates
including cortactin, Crk, integrin and p190RhoGAp (44,48-50).

Mechanistic overview of the structure and dynamic regulation of
Abl family kinases

Leukemia and tyrosine kinase inhibitors
The catalytic activity of Abl family kinases is tightly regulated through a complex
set of intermolecular and intramolecular interaction and post-translational
modifications (25-29). Inappropriate kinase regulation drive leukemia
development and promote solid tumor progression (4-6,23,51,52). One of the
best examples is the discovery of breakpoint cluster region (Bcr)-Abl1 fusion
protein, which is considered as the hallmark oncogenic protein that drive over
90% of Chronic Myelogenous Leukemia (CML) and a smaller subset of Acute
Lymphocytic Leukemia (ALL) (3,53). Bcr-Abl1 is a fusion protein resulting from
chromosomal translocation between chromosome 9 and 22 known as
Philadelphia chromosome (3). Several additional Abl1 and Abl2 fusion
oncoproteins since been discovered including Etv6-Abl1 and Etv6-Abl2 (54). One
common feature of these fusion Abl family kinases is its deregulated,
constitutively-active tyrosine kinase activity that drive multiple signaling pathways
5

and leading to loss control over cell proliferation, differentiation and adhesion
(54-56). Model for Bcr-Abl1 kinase activation suggested that the transforming
activity of Bcr-Abl1 requires the coil-coil domain from the Bcr moiety, which
mediates dimerization or tetramerization of Bcr-Abl1 (Fig 1.2) (57,58).
Oligomerization of the kinases promote intermolecular autophosphorylation of the
activation loop and other sites and lead to full catalytic activity (54,57). Disrupting
coiled-coil domain oligomerization by mutation or using a peptide competitor
reduces kinase and transforming activity, which support this activation model (Fig
1.2) (54,57,59,60).

Figure 1.2 Model for Bcr-Abl Kinase Activation
Oligomerization of Bcr-Abl1 through the Bcr coil-coil domain promote kinase
hyperactivation through intermolecular phosphorylation of key regulatory
tyrosines. In addition, oligomerization and phosphorylation disrupt the autoinhibitory interactions within the Abl N-terminal domains. Figure adapted from
(57).
6

The development of small molecular inhibitors that target Bcr-Abl1 for the
treatment of Chronic Myelogenous Leukemia (CML) was a major breakthrough
that marked the era of targeted therapies. The discovery of Imatinib, also known
as “Gleevec”, was widely regarded as the most successful cancer therapeutic
ever developed. Although imatinib has proved to be remarkably successful for
treating CML, many imatinib resistant mutations had been identified in patients.
To overcome this disadvantage, several generations of ATP-competitive Abl
kinase inhibitors including dasatinib, ponatinib, nilotinib and bosutinib were
developed and approved by FDA (61).They were designed to bind both the
inactive (nilotinib and ponatinib) and active (dasatinib and bosutinib)
conformations of the Abl kinase activation loop. Furthermore, allosteric inhibitors
including GNF-2 and GNF-5 were developed to target the myristoyl-binding
pocket in the C-lobe of the Abl kinase domain in an attempt to bypass the T315I
“gatekeeper” resistant mutation (62). A combination treatment of GNF-5 with
imatinib or nilotinib was shown to prolong the survival in a Bcr-Abl1 T315Iinduced leukemia mouse model (62). Therefore, the combine use of ATPcompetitive and allosteric inhibitors represents an innovative and effective
strategy to overcome resistance to either type of inhibitor alone. Besides their
success in the clinical setting, these tyrosine kinase inhibitors were used in many
co-crystal structures with Abl kinases, and provide great insight to the
understanding of Abl kinase regulation (62-64) .
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The “latch-clamp-switch” mechanism: Comparison between Abl and Src.
Similar to Src-family kinases, Abl family kinases are regulated via the “latchclamp-switch” mechanism (Fig 1.3A) (54,65). In their natively inactive state, both
Src and Abl kinase domains are held in a rigid conformation through
intramolecular interaction with their respective SH3 and SH2 domain; The SH3
and SH2 domain acts as a “clamp” and form an inhibitory scaffold that fold along
the back of the kinase domain, and this clamp is held together with the aid of
molecular “latch” (Fig 1.3A) (27,54,65). Despite the high degree of conservation
in the N-terminal domains of Abl and Src, there is significant difference on their
detailed regulatory mechanism which contritbue to their distinct cellular function –
the main difference being the “latch”. In the case of Src, the latch is an
intramolecular interaction betweeen the SH2 domain and phosphotyrosine
(pY527) on the C-terminal tail (65). Phosphorylation of Src Y527 by other kinases
inhibit Src kinase activity, while dephosphorylation of pY527 by phosphatase
activate it (66,67). However, in the case of Abl family kinases, the N-terminal
myristoyl group binding to the hydrophobic cavity of the kinase C-lobe serves as
a latch by inducing a conformational change in the C-terminal kinase domain
helix which allows the docking of SH2 domain on to the kinase C-terminal lobe
(27,68). Stimulation of Abl and Src family kinases is initiated by releasing the
latch and clamp, allowing the kinase domain to be flexible (Fig 1.3B). This
process is usually achieved by engagement of the SH3 and SH2 domain with
cellular binding partners (44,68,69). For full kinase activation, both Src and Abl
fmialy kinases need to be phopshoryalted on several key tyrsoine resides
8

(45,46,65). Phosphorylation is believed act as a “switch” and promote the
adoption of an active kinase state, preventing the return back to its inactive state
(Fig 1.3B) (65).

Figure 1.3 Abl and Src kinase are autoinhibited vis a “latch-clamp-switch”
mechanism (Figure caption on next page)
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Figure 1.3 Abl and Src kinase are autoinhibited vis a “latch-clamp-switch”
mechanism
(A) Comparison of the “latch-clamp-switch” autoinhibitory structure between Src
(PDB: 2SRC) and Abl1 (PDB: 1OPK). For both kinases, the SH3 and SH2
domain form the clamp that inhibit the kinase domain. For Src, intramolecular
interaction between the SH2 domain and phosphotyrosine (pY527) on the Cterminal tail latches the clamp. For Abl, the N-terminal myristoyl group binding to
the hydrophobic cavity of the kinase C-lobe serves as a latch by inducing a
conformational change in the C-terminal kinase domain helix that allows the
docking of SH2 domain on to the kinase C-terminal lobe. As for both kinases,
tyrosine phosphorylation within the kinase domain serves to “switch on” the
kinase activation loop. (B) Model of Abl family kinase activation propose that
engagement of the SH3 and SH2 domains with cellular binding partners release
the “clamp”. Subsequent phosphorylation both at the Abl1/Abl2 SH2-kinase linker
(Y245/Y272) and Abl1/Abl2 activation loop (Y412/Y439) act as a switch and
promote the adoption of an active kinase state. Figure adapted from (54,65)
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The Abl myristoylated N-cap is important for kinase regulation.
The Abl family kinases N-cap is about 80 amino acids in length and is
myristoylated in the Abl1 1b (IV in mouse) and Abl2 1b isoform (Fig 1.1). The
myristoyl group is a saturated long-chain fatty acid with a 14-carbon backbone.
The crystal structure of the autoinhibited Abl1 core revealed that the N-cap
myristoyl group buries in a deep hydrophobic pocket in the base of the kinase Clobe with micromolar affinity (Fig 1.4A) (27,68). Myristoyl group binding induces
a conformational change in the kinase domain αI helix, bending it 90° and
allowing the SH2 domain to dock onto the kinase C-lobe (Fig1.4B) (27). Without
the myristoyl group, the kinase αI helix is extended, causing a steric clash with
the SH2 domain and disrupting the interaction (27). Interaction of the
myristoylated N-cap with the kinase domain is important in maintaining Abl
kinase in an autoinhibited conformation, as deletion or mutation of the
myritoylation signal sequence leads to increased kinase and transforming activity
(68,70). As aforementioned, small molecules GNF-2 and GNF-5 that bind to the
myristoyl pocket act as allosteric inhibitors to regulate Abl kinase activity (62).
Crystal structure of the modified N-Cap also reveal that there are multiple contact
points between the N-Cap and the SH3/SH2 domains. Phosphorylated Ser69
can form hydrogen bond with Ser146 in the linker between SH3 and SH2,
providing additional regulatory switch (71).
Although protein myristoylation is implicated in targeting proteins to the cell
membrane, Abl N-cap myristoylation does not appear to play a major role in the
localization of Abl kinases (68). Mutated non myristoylated Abl1 was not
11

differentially localized in cell compare to myristoylated Abl1(68). The cytoskeletal
interaction domains in C terminal half of Abl kinases may be the major
determinant of cellular localization as discussed before (Fig 1.1) (18,29,31).

Figure 1.4 The Abl myristoyl group binds to the hydrophobic pocket in the
Abl kinase domain to regulate its activity. (Figure caption on next page)
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Figure 1.4 The Abl myristoyl group binds to the hydrophobic pocket in the
Abl kinase domain to regulate its activity.
(A) (Left) Molecular surface of Abl1 kinase domain (PDB entry 1OPJ).
Hydrophobic sidechains are colored as green. (right) Space fill model showing
that the Abl myristoyl group binding in the hydrophobic pocket of the kinase
domain.
(B) The interface of the SH2 domain and the kinase domain is highlighted in the
autoinhibited structure of Abl1 (PDB entry 2FO0). The αI helix of the kinase
domain (colored cyan) is rotated away from the SH2 domain, allowing SH2
(colored blue) to dock onto the kinase domain through pi-stacking interaction
between Tyr158 and Tyr361. Figure adapted from (27,71,72)
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The Abl SH3 domain, SH2-Kinase linker and the Kinase N-lobe form a
sandwich like interaction.
Like other SH3 domain, the Abl SH3 domain binds to proline-rich peptide that
form a poly proline type II (PPII) helix. In the auto-inhibited Abl kinases, the SH3
domain binds to the proline rich linker between the SH2 and kinase domains,
which adopt a PPII helical conformation (Fig 1.5) (27,35,71,73). Mutations of the
SH3 domain or the linker prolines perturbs this intramolecular interaction thereby
activating Abl kinase activity (33,34,68). Direct competition with a proline-rich
ligand or protein can also result in kinase activation (74,75). Interestingly, the
second proline residue of the PXXP motif in the SH2-kinase linker is replaced by
Tyr 245 in Abl1 (Tyr272 in Abl2). This tyrosine residue points away from the SH3
domain and packs into a hydrophobic crevice of the kinase N-lobe (27).
Therefore, the SH2-kianse linker acts as a glue, sandwiched between the SH3
and kinase domain to mediate the clamping mechanism (27).
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Figure 1.5 Abl SH3 domain interacts with the SH2-kinase linker

The position of the SH3 domain (red) and the SH2-kinase linker (orange) is
highlighted in the autoinhibited structure of Abl1 (PDB entry 2FO0). The linker
between SH2 and kinase domain form a PPII helix that interacts with the SH3
domain. Three regulatory tyrosine sites are also shown here. Figure adapted
from (72)
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The Abl SH2-kinase interaction changes dramatically between the inactive
and active conformation.
As discussed above, the role of Abl SH2 domain in regulating Abl kinase activity
differs from Src family kinase. The Src SH2 domain binds to the phosphorylated
Tyr527 residue on the C-terminal tail, which serves as a “latch” in the
autoinhibited conformation (Fig1.3) (65). In contrast, the phosphotyrosine-binding
function of Abl SH2 domain does not contribute to the auto-inhibited
conformation. Instead, it forms an extensive interaction interface with the Abl
kinase C-lobe (27). The binding of the myristoyl group to kinase C-lobe
hydrophobic pocket induces a conformational change of the αI helix to allow SH2
docking (27). Mutations that disrupt the SH2-kinase binding interface increase
kinase activity (68). In the autoinhibited conformation, Abl SH2-kinase interface
partially occludes access of phosphotyrosine ligand to the SH2 binding pocket,
suggesting that the phosphotyrosine ligand or another Abl SH2 binding partner
may break the SH2-kinase interaction hence activating kinase activity (27,44). A
few structural studies have suggested that the Abl SH2 domain undergo
significant rearrangement upon kinase activation (27,71). In the active state, Abl
adopts an elongated configuration, where the SH2 domain no longer binds to the
kinase C-lobe, but forms an extensive interface with the kinase N-lobe (Fig1.6)
(71). Since the SH2 domain is on “top” of the kinase domain, this conformation is
referred as the “top-hat” conformation (Fig1.6). Furthermore, the interaction
between SH2 and the kinase N-lobe mediates allosteric activation of the kinase
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domain (76). Mutations that disrupt the SH2/ kinase N-lobe interface impairs Abl
kinase activity (77,78).

Figure 1.6 SH2-kinase interaction in active Abl1
The Abl1 SH2 domain interacts with the kinase domain N-terminal lobe to
stabilize an active “top-hat” conformation. Key interaction resides are indicated.
Figure adapted from (71).
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Abl kinases are regulated by phosphorylation.
The auto-inhibited Abl kinases are regulated through a complex set of
intramolecular interaction, and it is not phosphorylated on tyrosine residues
(27,45,68,79). Disruption of the inhibitory interactions by mutagenesis result in
higher Abl phosphotyrosine content, which positively correlates with increased
kinase activity (34,45). Tyrosine phosphorylation in the kinase activation loop, the
SH3 domain, the SH2-kinase linker, and elsewhere contributes to kinase
activation, usually by disrupting regulatory intramolecular interactions. One
example is the autophosphorylation of Abl1 Tyr245 (Tyr 272 in Abl2) in the SH2kinase linker greatly increasing kinase activity, which results from disruption of
the SH3/linker or the linker/kinase N-lobe interactions (45,46). Consistent with
this, recent studies demonstrated that phosphorylation of Abl1 Tyr89 and Tyr134
(Tyr116 and Tyr161 in Abl2) prevents engagement of Abl SH3 domain with the
SH2-kinase linker and are associated with enhanced Abl kinase activity (Fig 1.5)
(80,81). Phosphorylation on the Abl kinase activation loop (Tyr412 in Abl1 and
Tyr439 in Abl2) was proposed to stabilize a conformation that is more compatible
with substrate biding and catalysis, thus increase its kinase activity (45,46).
There are other Abl kinase phosphorylation sites identified using mass
spectrometry (82-84). More studies are required to determine if these
phosphorylation events have any role in regulating kinase activity or in specific
cellular functions.
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Pathways and receptors that activate Abl family kinases
Abl family kinases are activated by diverse upstream pathways and stimuli
including receptor tyrosine kinases, adhesion receptors, immune cell receptors,
DNA damage, cytokines and microbial invasion (Fig 1.7) (10,11,24,44,47,85-90) .
This section will focus on the molecular mechanism by which different cell
receptors signaling activate Abl kinases.

Figure 1.7 Multiple cell receptors activate Abl family kinases.
Abl family kinase are activated by diverse receptor singling including receptor
tyrosine kinases, immune receptors and adhesion receptors. Abl kinases
translate diverse extracellular signals to regulate cell proliferation, survival,
migration and adhesion. Figure adapted from (90).
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Activation of Abl kinases through integrin receptor signaling.
Integrins comprise of a large family of transmembrane adhesion receptors that
provide a dynamic and bi-directional structural and signaling connection between
the extracellular matrix and intracellular cytoskeleton (91). Early studies found
that fibroblast plated on fibronectin or integrin cross-linking antibody have
increased Abl1 kinase activity, as well as relocalization of Abl1 to early focal
adhesions (92). Since then, our lab and others have further dissected the cellular
functions by which integrin signaling promotes Abl kinase activation in a variety
of cell contexts. Different studies show that integrin signaling induces Abl kinases
dependent membrane protrusions which results from the phosphorylation of
several Abl kinases substrate including p190RhoGAP and cortactin
(18,31,50,88,93). Furthermore, laminin, an integrin ligand, acts through integrinAbl1/Abl2-p190RhoGAp signaling cascade to regulate dendritic spine density
and neurite branching (94-96). Our lab has recently demonstrated that Abl2
kinase domain directly interacts and phosphorylates integrin β1 cytoplasmic
domain on Tyr-783. This phosphotyrosine then provide another binding interface
for Abl2 SH2 domain, and these interfaces mediate integrin β1-Abl2 interactions
in cells and enhance Abl2 kinase activity (Fig1.8) (44).
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Figure 1.8 Model for Abl2 kinase activation by integrin β1
Abl2 kinase domain binds to the lysine rich region of integrin β1 cytoplasmic
domain and phosphorylation Tyr783 residue. The phosphotyrosine provide
additional binding interface for Abl2 SH2 domain. These indirect interaction
interfaces may disrupt the autoinhibitory conformation of Abl2, leading to kinase
activation. Figure adapted from (44)
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Activation of Abl kinases through immune cell receptor signaling
The hypothesis that Abl family kinase might have a role in immune B and T cell
receptors signaling came from early studies suggesting that mice lacking Abl1 or
Abl C-terminal half exhibited immune deficit phenotypes i.e. increased
susceptibility to infection, and harboring smaller thymus and spleen sizes (97,98).
Abl1 deficient mice also showed decreased B and T cell numbers (98). Later
studies show that Abl1 kinase activity and protein level is increased upon B cell
receptor (BCR) activation in B-cell lines. This study also shows that BCR
coreceptor CD19, as a substrate of Abl1 kinase, was phosphorylated after B-cell
activation, resulting in the recruitment of Abl1 and other SH2 containing proteins
(99). To investigate the potential role of Abl kinases in T cell signaling, a study
showed that endogenous Abl kinases are activated following T cell receptor
(TCR) stimulation, and the activation partially requires Src family kinase Lck (14).
This study further identified ZAP-70 and LAT as substrates of Abl kinases;
pharmaceutical inhibition of Abl kinases activity with STI571 or reduced Abl
kinases expression results in decreased phosphorylation of ZAP-70 and LAT.
Conditional knock out of Abl1 and Abl2 in primary T cells show impaired TCR
dependent activation of ZAP-70, LAT, Jnk, Shc and PLCγ1 (14). These studies
showed that Abl kinases acts downstream of immune B and T cell receptors
signaling, and are required for linking pre-receptor stimulation to
activation/phosphorylation of downstream signaling molecules (14,99). However,
the molecular mechanism by which Abl kinases are activated by immune cell
receptors signaling remains unclear. The specific role of Abl kinases in
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phosphorylating multiple signaling molecules under immune receptor signaling is
yet to be determined.

Activation of Abl kinases through growth factor receptors
Early studies suggest that growth factor including platelet-derived growth factor
(PDGF) and epidermal growth factor (EGF) stimulation promote Abl family
kinases activation (47,85,86). Both Src family kinases and phospholipase C-γ1
(PLC-γ1) are required for the full activation of Abl kinases by growth factor
receptors (47,85,86). Src family kinases phosphorylate Abl kinases on the
activation loop, and PDGF activation of Abl kinases is reduced in src -/-yes-/-fyn-/cell lacking Src kinase activity (45,46,85). In addition, PLC- γ1 plays an important
role in this pathway by hydrolyzing PI(4,5)P2, which is identified as an Abl
kinases inhibitor (47,86). Our lab and others showed that Abl kinases mediate
the biological effect of PDGF-induced dorsal membrane ruffles, cell proliferation
and chemotaxis (47,48,85-87). EGFR and PDGFR also promote Abl kinase
activity in different cancer cells (4,5,7,100). PDGFR signaling through Abl1 is up
regulated during the development of resistance to aromatase inhibitor treatment
in breast cancer (101).
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Thesis project aims and my contributions
1. To determine the molecular mechanism by which Platelet Derived
growth factor receptor beta (PDGFRβ) activates Abl2.
This project started from an interesting preliminary discovery that PDGFRβ
interacts with Abl2 in vitro with sub-micromolar affinity using microscale
thermophoresis. With previous studies showing that PDGF stimulation promote
Abl2 kinase activity, I continued with this initial finding and determined the
molecular mechanism by which PDGFRβ interacts with, phosphorylates, and
activates Abl2 kinase (details described in Chapter 2). I found that phospho-Y771
in PDGFRβ is required to interact with the Abl2 SH2 domain both in vitro and in
cells. I demonstrated that PDGFRβ directly phosphorylates Abl2 on multiple
novel sites within the SH3/SH2-kinase linker interface, which normally acts to
keep the Abl2 in the auto-inhibited conformation. (Phosphopeptide mapping with
mass spectrometry is performed in collaboration with Dr.Yougjoo Kim in Dr.
Karen Anderson’s lab and Dr. Hanzhi Wu in Dr. Cristina Furdui’s lab). I showed
that PDGFRβ phosphorylation on Abl2 results in Abl2 kinase activation both in
vitro and in cells. Mutation of the PDGFRβ phosphorylation sites on Abl2 to
nonphosphorylatable residues abrogate PDGFRβ-mediated activation of Abl2
kinase activity. Together, these findings provide a molecular mechanism to
understand how receptor tyrosine kinases active Abl family kinase through
different phosphorylation events.
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2. To determine whether PDGFR regulates integrin activation through
Abl2 signaling.
This project started from an interesting discovery that PDGF stimulation
promotes Abl2-integrinβ1 interaction by a former graduate student, Adam
Simpson. He also found that Abl2 directly binds and phosphorylates integrin β1.
Interestingly, Abl2’s binding sites on integrin β1 overlap with those of talin, which
is an important integrin intracellular activator. I continued with this initial finding
and later discovered that PDGF stimulation also promotes Abl2 phosphorylation
on integrin β1 Y783, which had been shown to block talin’s binding on integrin
β1(102,103). Therefore, I hypothesized that PDGFR signaling may regulate talinmediated integrin activation through either direct competition or phosphorylation
(details described in Chapter 3). I found that Abl2 competes with talin for integrin
β1 binding in pull down assays. In collaboration with Dr. Maddy Parsons using
Förster resonance energy transfer by fluorescence lifetime imaging microscopy
(FLET-FLIM), we found that Abl2 expression led to a strong decrease in
interaction between integrin β1 and talin in response to PDGF stimulation in cell,
and this effect is greatly reduced in Abl2 knock down cell. In collaboration with
Daniel Iwamoto in Dr. David Calderwood’s lab, we used a Fluorescenceactivated Cell Sorting (FACS) based assay to measure integrin activation.
Unfortunately, results consistently show that there is no significant effect on
integrin activation after PDGF stimulation or Abl2 overexpression. Nonetheless,
these studies provide a basis for future studies in dissecting the molecular
mechanism by which PDGFR signaling regulate cell adhesion, migration and
invasion through Abl2/talin/integrin interactions.
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CHAPTER 2- PLATELET-DERIVED GROWTH FACTOR
RECEPTOR BETA ACTIVATES ABL2 THROUGH DIRECT
BINDING AND PHOSPHORYLATION.
Abstract
The catalytic activity of Abl family kinases is tightly regulated in cells by a
complex set of intermolecular and intramolecular interactions and posttranslational modifications. Abl kinases are activated by diverse cellular stimuli,
one of them is receptor tyrosine kinase signaling. PDGFRβ is identified as a
potent activator of Abl family kinases, and these kinases mediate the biological
effects of PDGF. However, molecular mechanism by which PDGFRβ engages
and activates Abl family kinases is not known. Here, we report the molecular
mechanism by which PDGFRβ interacts, phosphorylates and activates Abl2
kinase. We found that PDGFRβ binds and phosphorylates Abl2 both in vitro and
in cells. We also identified several novel PDGFRβ phosphorylation sites on Abl2,
including Y116, Y139 and Y161 on the SH3 domain, Y299, Y303 and Y310 on
the kinase domain. Of notable interest, Y116, Y161, Y272 and Y310 are all
located near the SH3/SH2-kinase linker interface, which help maintain Abl family
kinases in an auto-inhibited conformation. Mutation of these four tyrosine (Y116,
Y161, Y272 and Y310) to phenylalanine abrogated PDGFRβ-mediated activation
of Abl2 kinase activity. These findings provide a mechanism to understand how
receptor tyrosine kinases activate Abl family kinases, and how Abl kinase are
precisely regulated through different phosphorylation events.
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Introduction
Abl family nonreceptor tyrosine kinases, comprised of Abl1 and Abl2 in
vertebrates, translate signals from growth factors and adhesion receptors to
regulate cytoskeleton organization and remodeling, which is essential to many
cellular processes including cell morphogenesis, adhesion and migration (1-9).
The catalytic activity of Abl family kinases is important in promoting actin-based
cell edge protrusions, facilitating endocytosis and phagocytosis, mediating DNA
damage responses, and regulating cell survival and proliferation in a variety of
cell contexts. These processes play essential roles in the development and
function of the cardiovascular, brain, and immune systems, among others
(6,8,10-19).
The catalytic activity of Abl family kinases is tightly regulated, and
inappropriate kinase regulation drives leukemia development and promotes solid
tumor progression (18,20-24). The kinase activities of Abl1 and Abl2 are
regulated by a complex set of intermolecular and intramolecular interactions and
post-translational modifications (25-29). Non-activated Abl kinases are kept
inactive via an autoinhibitory mechanism, in which the kinase domain is held in a
rigid conformation through intramolecular interactions with the SH3 and SH2
domains (27-30). Models for kinase activation proposed that engagement of SH3
and SH2 domains with cellular binding partners relieves this inhibition.
Subsequent tyrosine phosphorylation events promote adoption of an active
conformation and prevent returning back to the inactive conformation
(9,25,26,29,31). Endogenous Abl kinases are activated by diverse stimuli
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including growth factors, cytokines, DNA damage and adhesion receptors (14,7,9,31,32).
Abl family kinases are activated downstream of receptor tyrosine kinases
in fibroblast and cancer cells, including the epidermal growth factor receptor
(EGFR) and platelet-derived growth factor receptor (PDGFR) (1,2,7,18,21,23).
The PDGFRβ is an especially potent activator of Abl family kinases, and Abl
kinases mediate the biological effects of PDGF including PDGF-induced dorsal
membrane ruffles, cell proliferation and chemotaxis (1-3,7,33). PDGFR signaling
through Abl1 is upregulated during the development of resistance to aromatase
inhibitor treatment in breast cancer (34). Previous work showed that the PDGFRβ
binds Abl kinases and this is associated with increased Abl kinase activation (13,7), but the molecular mechanism by which PDGFRβ engages and activates Abl
family kinases is not known.
Here we report the molecular mechanism by which PDGFRβ interacts
with, phosphorylates and activates Abl2 kinase. We found that PDGFRβ binds
and phosphorylates Abl2 both in vitro and in cells. We also identified several
novel tyrosine (Y) phosphorylation sites on Abl2 including Y116, Y139 and Y161
on the SH3 domain and Y299, Y303 and Y310 on the kinase domain. Of notable
interest, Y116, Y161, Y272 and Y310 are all located near the SH3/SH2-kinase
linker interface, which is crucial for keeping Abl2 in an auto-inhibited
conformation. Mutation of Y116, Y161, Y272 and Y310 to phenylalanine
abrogated PDGFRβ mediated activation on Abl2. These findings provide a
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mechanism to understand how Abl family kinases are regulated by receptor
tyrosine kinases through different phosphorylation events.

Results

The Abl2 SH2 domain binds to phosphotyrosine 771 in PDGFRβ.
Previous work demonstrated that Abl2 co-immunoprecipitates with PDGFRβ from
cell lysates (47), but whether the PDGFRβ binds Abl2 directly or which interfaces
mediate this interaction are not known. Upon activation by PDGF binding, the
PDGFRβ cytoplasmic domain undergoes tyrosine autophosphorylation at
multiple sites, which recruit key adaptor and signaling proteins. We hypothesized
that Abl2 SH2 domain directly binds one or more of these phosphotyrosines.

PDGFRβ was expressed in HEK293 cells and activated by stimulation with
PDGF-BB (PDGF). Following stimulation, we found that PDGFRβ could be
retained on Abl2 SH2-domain containing agarose beads, but not to beads
containing the Abl2 SH2 R198K point mutation that disrupts SH2 binding to
phosphotyrosine-containing binding partners (18,104) (Fig 2.1B). In parallel, the
kinase-inactive PDGFRβ point mutant (K634R) did not undergo PDGF-stimulated
autophosphorylation and was not retained on Abl2 SH2 beads (Fig 2.1A, B).
These data indicated that autophosphorylated PDGFRβ in cell lysates can bind
the Abl2 SH2 domain.
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PDGFRβ is phosphorylated at multiple sites in cells, some or all of which could
be binding interfaces for the Abl2 SH2 domain, but previous studies have not
resolved which phosphotyrosine (pY) residue of PDGFRβ serve as binding sites
for the Abl2 SH2 domain. To address this, we mutated specific tyrosine residues
in the PDGFRβ cytoplasmic domain to phenylalanine and expressed the mutants
in HEK293 cells. All mutants were expressed at similar levels and underwent
significant tyrosine phosphorylation following PDGF-BB treatment, but binding of
the PDGFRβ Y771F mutant to Abl2 SH2 domain beads was reduced by 90%
relative to WT PDGFRβ or any of the other Y to F single substitution mutants of
PDGFRβ (Fig 2.1C, D). Binding of PDGFRβ Y751F was also reduced, but only
by 10% relative to wild type controls. (Fig 2.1C, D) These data suggest that
phospho-Y771 in PDGFRβ is required to interact with the Abl2 SH2 domain.

Before I perform the mutagenesis study to determine the binding interface
between Abl2 and PDGFRβ, we also looked at SH2 screen publications and try
to find a clue about potential binding interfaces with the help of Dr. Kazuya
Machida. Even though most of studies have not determined or detected
PDGFRβ/Abl2 interactions, these studies provide some insight (41,105). For
example, a florescence polarization based high throughput screen show some
consensus residues for known receptors that interact with Abl2 (Fig 2.2) (105).
SH2 domain bind to phosphotyrosine-containing peptides with sequence
specificity. Different SH2 domains have different preferences regarding the three
to six amino acid residues downstream from the phosphorylated tyrosine (38,39).
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Interestingly, the binding motif for PDGFRβ pY771 YMAP is similar to some
known receptors that binds to Abl2. M in the first residue position and P in the
third residue poison after the phosphotyrosine appear in a lot of Abl2 SH2
binders (Fig 2.2).

Figure 2.1 The Abl2 SH2 domain binds phosphorylated PDGFRβ. (Figure
caption on next page)
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Figure 2.1 The Abl2 SH2 domain binds phosphorylated PDGFRβ.
(A) HEK293 cells either untransfected (control) or transfected with PDGFRβ or
kinase inactive (KI) PDGFRβ were serum starved overnight and treated with 100
ng/ml PDGF-BB for 10 minutes. 40 μg of lysate were immunoblotted with
antibodies to PDGFRβ, phosphotyrosine-751 in PDGFRβ, or phosphotyrosine
(4G10). Bottom panel shows the Ponceau S-stained blots as loading controls.
Molecular weight markers are indicated. Significant tyrosine phosphorylation is
shown by western blotting using both nonspecific phospho-tyrosine antibody and
a specific phosphor-Y751 PDGFR antibody. (B) Agarose beads covalently
coupled to WT Abl2 SH2 domain and phosphotyrosine-binding defective (R198K)
Abl2 SH2 mutant were incubated with 500 μg HEK293 cell lysates expressing
WT and KI PDGFRβ that were mock treated or stimulated with PDGF-BB after
overnight serum starvation as in (A). WT Abl2 SH2 domain pull down PDGFRβ
that had been stimulated with PDGF-BB. (C) (top 3 panels) Wild type and
tyrosine (Y) to phenylalanine (F) PDGFRβ mutants (Y716F, Y751F and Y771F)
were transiently expressed in HEK293 cells and stimulated as in (A). 40 μg of cell
lysate was immunoblotted for PDGFRβ or phospho-tyrosine, while bottom panel
shows Ponceau S staining as control. (bottom panel) 500 μg of the indicated
lysates were incubated with beads coupled to the Abl2 SH2 domain and the
bound material was immunoblotted for PDGFRβ. (D) Quantification of PDGFR
pull down by Abl2 SH2 domain.
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Figure 2.2 Summary of receptors that binds to Abl2 SH2 domain show
consensus residues. (A) Prediction of Abl kinases SH2 binder’s consensus is
shown. (B) Summary of the binding sequence for other receptors that interacts
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with Abl2 SH2 domain. Similar sites in PDGFR are highlighted. Data summarized
from (105).

We next used purified recombinant Abl2 SH2 domain and PDGFRβ cytoplasmic
domain (CD) to test whether the proteins interact directly and to measure the
affinity and specificity of this interaction. The PDGFRβ CD was comprised of the
residues spanning from C-terminal end of the transmembrane region to the Cterminus of the protein (554M-1106L). We purified 6XHis-tagged PDGFRβ CD
following baculovirus-mediated expression in insect cells, fully dephosphorylated
it in vitro using phage lambda phosphatase, and re-purified the dephosphorylated
PDGFRβ CD (Fig 2.3A). We incubated PDGFRβ CD in the presence of
saturating Mg2+ and ATP for 2 hours to enable it to autophosphorylate to
completion (Fig 2.3A). Purified autophosphorylated PDGFRβ CD bound to the
Abl2 SH2 domain beads with sub-micromolar affinity (Kd= 0.26 േ 0.07 μM), while
the non-phosphorylated PDGFRβ CD only exhibited weak background binding
(Fig 2.3B). As in experiments using cell-derived PDGFRβ (Fig 2.3B), the binding
defective Abl2 SH2 domain R198K mutant completely abolished binding to autophosphorylated PDGFRβ CD (Fig 2.3C). While the PDGFRβ CD Y771F mutant
was able to autophosphorylate in vitro, it did not bind significantly to Abl2 SH2
domain-containing beads (Fig 2.3A, D, E). Together, our data indicate that the
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Abl2 SH2 domain binds directly to phosphorylated Y771 interface on the PDGFR
cytoplasmic domain.

Figure 2.3 Abl2 SH2 directly binds phosphorylated PDGFRβ cytoplasmic
domain in vitro. (Figure caption on next page)
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Figure 2.3 Abl2 SH2 directly binds phosphorylated PDGFRβ cytoplasmic
domain in vitro.
(A) Coomassie Blue-stained gel showing the purity of recombinant purified
proteins used in this figure. 50 ng of recombinant PDGFRβ CD were
immunoblotted with antibodies to PDGFRβ and phosphotyrosine (4G10). (B-E)
The concentration dependence of auto-phosphorylated PDGFRβ CD, nonphosphorylated PDGFRβ CD (B), and auto-phosphorylated PDGFRβ CD
(Y771F) (D) binding to Abl2 SH2 domain and phosphotyrosine-binding defective
(R198K) Abl2 SH2 mutant (C) were measured. An increasing concentration of
PDGFRβ CD from 0-2 μM in binding reaction were pulled down by agarose
beads covalently coupled to Abl2 SH2 at a final concentration of 1 μM. Pulldown
products were separated by SDS PAGE, and gel bands were resolved with
Coomassie blue stain and densities were quantified using ImageJ. One-site
specific binding isotherms fit using ImageJ was set to binding experiments. The
Kd value for phosphorylated PDGFR CD and Abl2 SH2 domain is 0.26 ± 0.07
μM. Error bars represent S.E. from n=3.
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PDGFRβ directly phosphorylates the Abl2 N-terminal half on multiple novel
sites.
Abl2 kinase activity is activated by phosphorylation (46). We used an in vitro
kinase assay to measure whether purified recombinant PDGFRβ CD
phosphorylates Abl2. We expressed MBP-Abl2 full length (encompassing the
first common exon to C-terminus), MBP-Abl2 C-terminus (residues 557-1182
around 120 Kda) and a 6XHis-tagged Abl2 N-terminus (residues 74-557) in
insect cells and purified them (Fig 2.4A). The Abl2 kinase domain-containing
constructs carried two inactivating mutations (D307N, K317M) in the kinase
domain, which eliminates possible Abl2 autophosphorylation. In the presence of
Mg2+ and ATP, 5 nM of recombinant PDGFRβ CD directly phosphorylated full
length Abl2 and the Abl2 N-terminus, but only very weakly the Abl2 C-terminus
(Fig 2.4B). We next investigated whether PDGFR/Abl2 direct interaction is
required for PDGFR to phosphorylate Abl2. PDGFRβ CD phosphorylation of the
Abl2 N-terminus (R198K) SH2 domain mutant, defective in binding, was greatly
reduced relative to WT Abl2 N-terminus (Fig 2.4C). These results suggest that
SH2 domain-mediated Abl2 recruitment to PDGFR is required for its
phosphorylation.
Phosphorylation of Abl2 at Y272 in the SH2 domain-kinase linker and Y439 in the
kinase activation loop can activate its kinase activity and Abl1 is similarly
activated via phosphorylation of those homologous sites (45,46). We mutated
these sites in the Abl2 N-terminus construct to test how this impacts
phosphorylation by the PDGFRβ CD. Unexpectedly, we found that the PDGFRβ
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CD could still phosphorylate Abl2 N-terminus Y272F/Y439F mutant with a similar
kcat (6.8 min-1 vs. 7.3 min-1) and KM (1.6 μM vs. 2.8 μM) as compared to WT,
suggesting that the PDGFRβ CD phosphorylates one or more novel sites in Abl2
(Fig 2.4D).
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Figure 2.4 PDGFRβ phosphorylates the Abl2 N-terminal half.
(Figure caption on next page)
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Figure 2.4 PDGFRβ phosphorylates the Abl2 N-terminal half.
(A) Domain architecture and purified recombinant protein of Abl2 and Abl2 Nand C-terminal halves. Purified proteins were separated by SDS-PAGE and
visualized by Coomassie Blue staining. The Abl2 kinase domain-containing
constructs carried two inactivating mutations (D307N, K317M, indicated red
lines) in the kinase domain to eliminate possible Abl2 autophosphorylation. (B)
Radioactive ATP Kinase assays were performed by preincubating 5 nM PDGFRβ
CD and 0-2 μM Abl2 constructs for 5 min at 32 °C before initiating reactions with
5 μM ATP and 0.75 μCi of [γ-32P] ATP for 10 min before terminating with 1X
LSB, running on gels, and exposing to a phosphor imaging screen. A parallel
assay was performed without [γ-32P] ATP addition, separated by SDS-PAGE
and visualized with Coomassie Blue. (C) Radioactive ATP Kinase assays testing
ability of PDGFRβ CD to phosphorylate Abl2 N-term and a phosphotyrosinebinding defective (R198K) Abl2 N-term mutant with PDGFRβ CD as kinase. A
parallel SDS PAGE visualized with Coomassie Blue is performed. (D) (top panel)
Radioactive ATP Kinase assays of WT Abl2 N-term and Abl2 N-term (Y272F
Y439F) mutant phosphorylated by PDGFRβ CD as kinase. (bottom panel) 020μM WT Abl2 N-term and mutant were preincubated incubated with 0.1 nM of
PDGFRβ CD in kinase assay conditions described in (B). Reactions were
quenched with 1X LSB after 10 mins, boiled, and separated on 10% SDS PAGE
and protein bands were stained with Blue Silver G-250 Coomassie to visualize
Abl2 N-term protein bands. Bands were cut out and scintillation counted. Counts
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per minute were converted and fit to Michaelis-Menten equation in GraphPad to
obtain kinetic parameters. Error bars represent S.E. from n = 3.

In order to identify the novel phosphorylation sites, we performed
phosphopeptide mapping with mass spectrometry (MS). Abl2N purified from
insect cells was treated with a mix of Lambda protein phosphatase and YopH for
dephosphorylation. Abl2N phosphorylated by PDGFRβ CD was monitored for
phosphorylation status at different time points. Samples immunoblotted for
phosphotyrosine show phosphorylation intensity saturates at 2 hours reaction
time (Fig 2.5A, top panel). Phos-tag SDS-PAGE successfully separated
unphosphorylated Abl2N and resolved multiple phosphorylated Abl2N species in
the PDGFRβ CD-treated samples. As kinase reaction time increases, the
intensity increases for higher phosphorylated states of Abl2N, while decreases
for lower phosphorylated sates and non-phosphorylated Abl2N (Fig 2.5A lower
panel). The phosphorylated Abl2N was used to perform phosphopeptide
mapping by MS to locate potential new phosphotyrosine residues. MS analysis
identified 7 tyrosine phosphorylation sites (Fig 2.5B), including phospho-Y439
which was previously identified as a Src family kinase-mediated phosphorylation
site (46) (Fig 2.5C), and several novel sites including phospho-Y161(Fig 2.5D).
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Figure 2.5: Phosphopeptide mapping with mass spectrometry identified
novel phosphorylation sites (A) Phosphorylated Abl2 sample was prepared by
incubating 1 μM of Abl2N (KI) with 10 nM of PDGFRβ and Mg2+/ATP. Reaction
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samples were terminated with 4X LSB at 1, 2 and 4 hours and monitored for
phosphorylation status. (top panel) 100 ng of the reaction sample was
immunoblotted with antibodies to phospho-tyrosine (4G10). (bottom panel) 10 μg
of reaction samples were separated by Phos-tag SDS-PAGE and visualized with
Coomassie Blue stain. (B) Summary of tyrosine phosphorylation sites that are
identified by mass spectrometry with Abl2N phosphorylated by PDGFRβ CD. (C)
The MS/MS spectrum is shown for example of peptides containing Tyr439 with
representative b and y fragment ions in red and blue respectively. (D) The
MS/MS spectrum of peptides containing Tyr161 with representative b and y
fragment ions in red and blue respectively.
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In parallel with the mass spec study, we used smaller sub fragments of Abl2N as
substrates to identify regions phosphorylated by PDGFRβ. We found that the
isolated tandem SH3 SH2 domain fragment, a fragment of the SH2 domain
containing the SH2-kinase linker, and the kinase domain were all phosphorylated
by PDGFRβ, indicating that PDGFRβ can phosphorylate multiple sites as MS
study suggests. To cross examined the MS study, we created a panel of Y to F
substitution of phosphotyrosine identified by MS and also Y116 which was
indicated by MS as a potential phosphorylation site but with lower confidence
(Fig 2.6A). Mutation of tyrosine 272 (Y272F) on the SH2-kinase linker completely
abrogated Abl2 SH2 domain phosphorylation by PDGFR, while the other triple
mutant constructs did not reduce phosphorylation (Fig 2.6B). Mutation of three
tyrosines in the SH3 domain (Y116F, Y139F and Y161) greatly reduces SH3SH2 domain phosphorylation by PDGFR (Fig 2.6C). Mutations of four tyrosines
in the kinase domain (Y299F, Y303F, Y310F and Y439F) also significantly
reduced its phosphorylation (Fig 2.6D). Our mutagenesis kinase assay was
consistent with MS findings. Interestingly, there are several novel
phosphorylated tyrosine residues (Y116, Y161, Y272 and Y310) located at or
near the SH3/SH2-kinase linker interface, which has an important regulatory role
of keeping Abl family kinases in an auto-inhibited conformation (Fig 2.6E) (71).
We hypothesize that PDGFRβ phosphorylation on these sites would disrupt the
autoinhibitory binding interfaces between SH3 and SH2-kinase linker, resulting in
Abl2 activation
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Figure 2.6: PDGFRβ phosphorylates Abl2 N-terminal half on several
tyrosine residues at the SH3/SH2-kinase linker interface. (A) Domain
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architecture of the smaller sub fragments of Abl2 N-terminal half and their mutant
constructs (red lines indicate relative point mutation position). The table
summarizes whether the construct is phosphorylated by PDGFRβ. (B) (top panel)
Radioactive ATP Kinase assays of WT Abl2 SH2 domain and Abl2 SH2 (Y272F)
mutant phosphorylated by PDGFRβ CD as kinase. (bottom panel) Radioactive
ATP Kinase assays of WT Abl2 SH2 domain, and two SH2 triple mutant
constructs. (C) Radioactive ATP Kinase assays of WT Abl2 SH3SH2 domain and
Abl2 SH3SH2 (Y116F, Y139F and Y161F) mutant phosphorylated by PDGFRβ
CD. (D) Radioactive ATP Kinase assays of WT Abl2 kinase (KI) domain and Abl2
Kinase (KI) (Y299F, Y303F, Y310F and Y439F) mutant phosphorylated by
PDGFRβ CD. (E) (Left panel) Crystal structure of the autoinhibited state c-Abl1
N-terminus (PDB code 2FO0) (71). The position of SH3 domain (orange), SH2
domain (green), SH2-kinase linker (black), kinase domain (blue). (Right panel)
Enlargement of the SH3/SH2-kinase linker interface. The SH2-kinase linker
adopts a PPII helix that engage the SH3 domain. Abl2 Y116 and Y161 (Y89 and
Y134 in Abl1) are located on the binding interface of SH3 domain that face the
linker. Abl2 Y272 (Y245 in Abl1) is located on the linker and face the N-lobe of
the kinase domain. Abl2 Y310 (Y283 in Abl1) is located on the kinase N-lobe and
face the linker.
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PDGFRβ phosphorylation activates Abl2 kinase activity.
Autophosphorylation of Y272 in Abl2 and phosphorylation of Y439 by Src family
kinases promotes Abl2 kinase activity (46). We tested if PDGFRβ CD
phosphorylation could activate the ability of Abl2 to phosphorylate its substrate
CrkII in vitro, using purified proteins (Fig 2.7A). We first incubated 1 μM of Abl2N
with 10 nM of PDGFRβ and Mg2+/ATP in a 1-hour activation reaction during
which we achieved significant tyrosine phosphorylation (Fig 2.7B). Control
preparations include PDGFRβ only, Abl2N without PDGFRβ/ATP (non-activated),
and Abl2N with ATP only (auto-activated) condition. Following these
preincubations, we used 1 nM of Abl2N in kinase reactions to phosphorylate
CrkII, and KM and kcat for the reaction were measured. The catalytic efficiency
(kcat/KM) value for the non-activated Abl2N was determined to be 0.55 μM -1min-1
and autophosphorylated Abl2 had a kcat/KM = 0.83 μM-1min-1, while the PDGFR
activated condition was 3.15 μM-1min-1. This result suggests that PDGFR
phosphorylation on Abl2N promotes a 5.7-fold activation over baseline and a 3.8fold activation over autophosphorylated Abl2N (Fig 2.7B, D)
To determine which tyrosine phosphorylation events contribute to Abl2 kinase
activation, we next mutated five tyrosines that structural modeling suggested
might be most relevant to Abl2 kinase activation (Y116F, Y161F, Y272F, Y310F
and Y439F) to create the Abl2N 5YF construct. Incubation with the PDGFRβ CD
did not result in Abl2N 5YF activation (Fig 2.7C, D). Src family kinase-mediated
phosphorylation of Abl2 on Y439 phosphorylation within its activation loop
promotes kinase activation (46). Hence, we also tested whether restoration of
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Y439, in a 4YF mutant (Y116F, Y161F, Y272F and Y310F) impacts activation of
Abl2N by PDGFRβ. Similar to the effects on the 5YF mutant, PDGFR
phosphorylation did not result in Abl2 4YF activation (Fig 2.7C, D). These data
suggest that PDGFR phosphorylation on one or more of the additional sites Y116, Y161, Y272 and Y310 contributes to activation of Abl2N kinase activity.

Figure 2.7. PDGFRβ phosphorylated Abl2 and modulate Abl2 kinase
activation in vitro. (Figure caption on next page)
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Figure 2.7. PDGFRβ phosphorylated Abl2 and modulate Abl2 kinase
activation in vitro.
(A) Coomassie Blue-stained gel showing the purity of all recombinant purified
protein used in this figure. (B) WT Abl2 N-terminus, 4YF (Y116F, Y161F, Y272F,
Y310F) Abl2-N and 5YF (Y116F, Y161F, Y272F, Y310F, Y439F) Abl2-N were
incubated with PDGFRβ in an activation reaction. Control conditions include
Abl2-N constructs without PDGFRβ/ATP (non-activated), and Abl2-N constructs
with ATP only (auto-activated). 100 ng of reaction product in all conditions were
immunoblotted with antibody to phosphotyrosine. (C, D) Kinase activity was
assayed by determining the kinetic parameter of GST-CrkII phosphorylation in [γ32P] ATP kinase assays. Measurement collected along an increasing
concentration (0-16 μM) of CrkII in each condition were fit to Michaelis-Menten
isotherms using GraphPad. Error bar represent the S.E from n=3 concentration
series for each condition. (E) KM, kcat and the catalytic efficiency (kcat/KM) values
of Abl2-N mediated GST-CrkII phosphorylation were calculated from isotherms fit
to perspective conditions shown in C and D.
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PDGFRβ binds and phosphorylates Abl2 in cells.
We next investigated whether PDGFRβ binds and phosphorylates Abl2 in cells.
PDGFRβ and Abl2-HA were co-expressed in HEK293 cells and stimulated with
PDGF. Both WT and kinase inactive PDGFRβ and WT and R198K Abl2-HA
expressed well at similar levels (Fig 2.8A). Only WT PDGFRβ underwent
significant tyrosine phosphorylation following PDGF treatment (Fig 2.8A). We
then immunoprecipitated Abl2 and measured Abl2 tyrosine phosphorylation
levels. In cells expressing WT PDGFRβ, PDGF stimulation significantly increased
Abl2 tyrosine phosphorylation levels by 2.2-fold, but similar increases in Abl2
tyrosine phosphorylation were not observed in PDGF stimulated cells expressing
kinase inactive PDGFRβ (Fig 2.8B, C). Similarly, stimulation of the PDGFRβ did
not increase tyrosine phosphorylation of the PDGFRβ – binding defective Abl2
R198K mutant. In fact, the basal tyrosine phosphorylation of the Abl2 R198K
mutant was significant lower relative to WT Abl2. PDGFRβ also coimmunoprecipitated with Abl2 after PDGF stimulation, but complexes were not
detected in transfections expressing either the PDGFR kinase inactive mutant or
the R198K Abl2 mutant. These data suggest that PDGFRβ signaling promote
Abl2 tyrosine phosphorylation and PDGFRβ/Abl2 interaction.
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Figure 2.8 PDGFRβ form a complex with Abl2 and phosphorylates Abl2 in
cells. (Figure caption on next page)
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Figure 2.8 PDGFRβ form a complex with Abl2 and phosphorylates Abl2 in
cells.
(A) HEK293 cells were either untransfected (control) or transfected with WT or
kinase inactive (KI) PDGFRβ and WT or R198K Abl2-HA. HEK293 cells were
serum starved overnight and treated with 100 ng/ml PDGF-BB for 10 minutes. 40
g of lysate were immunoblotted with antibodies to PDGFRβ, phosphotyrosine,
Abl2 or HSP70. Bottom panel shows the Ponceau S-stained blots as loading
controls. Molecular weight markers are indicated. (B) 500 mg of lysate in each
condition was immunoprecipitated with anti-HA antibody. Control lane represent
lysate pull down by protein-A/G beads without antibody. Immunoprecipitated
product were blotted with antibodies to Abl2, phosphotyrosine and PDGFRβ. (C)
Quantification of the normalized phosphotyrosine intensity shown in (B) from lane
2-7.
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PDGFR activates Abl2 kinase activity in Fibroblasts

Finally, we addressed whether PDGFRβ activation leads to Abl2-mediated
signaling events in cells. We used CRISPR in WT mouse 3T3 fibroblast cells to
achieve 90% reduction in Abl1 levels and 88% reduction in Abl2 levels (Fig
2.9B). Stimulation of WT mouse fibroblasts with PDGF leads to an eight-fold
increase in phosphorylation of the Abl1/Abl2 substrate CrkII (Fig 2.9A), but this
was significantly abrogated in Abl1/Abl2 CRISPR double knock out (DKO) cells.
However, we ascribe the small increase of CrkII phosphorylation after PDGF
stimulation to this residual Abl1/Abl2 level in the DKO cells.
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Figure 2.9 PDGFRβ signaling promotes Abl2 kinase activation in cells.
(A) (Top panel) WT and CRISPR Abl1/Abl2 dKO mouse 3T3 fibroblast cells were
serum starved overnight and treated with 100 ng/ml PDGF-BB for 10 minutes. 40
μg of lysate were immunoblotted with antibodies to PDGFRβ, phosphotyrosine751 in PDGFRβ, CrkII and phosphotyrosine-221 in CrkII. (Bottom panel)
Quantification of normalized p-CrkII/CrkII intensity. (B) (Top Panel) WT, CRISPR
Abl2 KO and CRISPR Abl1/Abl2 DKO mouse 3T3 fibroblast cells were
immunoblotted with specific antibodies to Abl1 and Abl2. Bottom panel shows
Ponceau S staining as loading control.
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Discussion and future directions
We report here the molecular mechanisms by which PDGFRβ binds,
phosphorylates, and activates the Abl2 kinase. We provide evidence that Abl2
binds to auto-phosphorylated PDGFRβ both in vitro and in cells via Abl2 SH2/
PDGFRβ phospho-Y771 interface. Abl2 recruitment results in PDGFRβ directly
phosphorylating the Abl2 N-terminal half on multiple sites. Using both kinase
assays with Tyr to Phe substitution Abl2 constructs and phosphopeptide mapping
with mass spectrometry, we identified up to 8 phosphotyrosine sites on Abl2. We
demonstrated that PDGFRβ phosphorylation on Abl2 results in Abl2 kinase
activation both in vitro and in cells. These findings provide a molecular
mechanism to understand how receptor tyrosine kinases activate Abl family
kinase through different phosphorylation events.

PDGFRβ may serve as a scaffold to coordinate Abl kinase activation with
other signaling outputs.
PDGF stimulation induces homodimerization of PDGFRβ as well as
heterodimerization of PDGFRα and PDGFRβ, resulting in receptor
autophosphorylation at multiple sites. These autophosphorylated Tyr residues
serve as docking sites to recruit and activate multiple SH2 domain- containing
singling proteins to elicit specific cellular responses (37,38). Some of these
effectors have intrinsic enzymatic activities including Src family kinases (SFK),
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phospholipase C- γ (PLC-γ), Ras-GTPase activating protein (Ras-GAP) and Src
homology phosphatase 2 (SHP2) (37-41). Among them, both SFKs and PLC-γ
had previously been shown to active Abl family kinases through different
mechanisms (1-3,25,26). Interestingly, SFKs bind sites on PDGFRβ
(pY579/Y581) that are distinct from the pY771 that recruits Abl2. Thus, the
PDGFRβ may serve as a scaffold to bring these proteins in proximity to promote
Abl2 activation. The dimerized form of PDGFRβ may also facilitate Abl2 Y272
autophosphorylation in trans, which also promotes kinase activation (25,26). We
anticipate that other cell receptors that activate Abl family kinases including
EGFR and integrin (4,9,21,42,43) may similarly use phospho-Y residues to
recruit the Abl kinases and co-regulators, thereby acting as platform for Abl
family kinase activation.
The identification of phospho-Y771 on PDGFRβ as an Abl2 binding site also has
implications for additional possible modes of Abl2 kinase regulation. For
example, the SHP2 tyrosine phosphatase specifically dephosphorylates Y771 in
PDGFRβ, which may restrict Abl recruitment to PDGFRβ (44). In addition, RasGAP also binds to pY771 (40) and it may compete with Abl2 and limit PDGFRβmediated Abl2 kinase activation by competing with Abl2 recruitment to the
receptor.
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Disruption of the SH3/SH2-kinase linker interaction through
phosphorylation may be a common mechanism in Abl kinase activation
In the inactive state, the Abl SH3 domain binds to the proline rich linker between
the SH2 and kinase domains, which adopt a polyproline type II (PPII) helical
conformation (28,45,46). Mutations of the SH3 domain and the linker prolines
perturbs this this intramolecular interaction thereby activating Abl kinase activity
(30,47,48). We found that PDGFRβ phosphorylates Abl2 on four interesting
tyrosines (Y116, Y161, Y272 and Y310) that are all located at or near the
SH3/SH2-kinase linker interface, which is critical to keep Abl family kinases in an
auto-inhibited conformation (Fig 2.6D) (28). Engagement of the Abl2 SH2 domain
with PDGFRβ is proposed to disengage this autoinhibited conformation.
Subsequent phosphorylation on one or more of these sites would prevent
reengagement of SH3 domain with the SH2-kinase linker and shift Abl2 into a
non-inhibited “open” activated conformation. Consistent with this, previous
studies demonstrated that phosphorylation of Abl2 Y116, Y161 and Y272 (Y89,
Y134 and Y245 in Abl1) or mutation of key P residues in the SH2 kinase linker
prevent engagement of Abl SH3 domain with the SH2-kinase linker and are
associated with enhanced Abl kinase activity (26,48-50). Abl2 SH3 domain
phosphorylation may also result in such extended conformation, which release
the SH2-kinase linker. This “opening” of the kinase likely also promotes the
autophosphorylation of the Y272 (Y245 in Abl1), an important step in Abl kinase
activation (25,26).
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Future experiments are needed to determine the role of other phosphorylation
sites on Abl2 by PDGFRβ. Interestingly, Y299 and Y303 are both located on a
highly conserved glycine rich P-loop in the kinase domain that contacts the
phosphate group of ATP. Their mutations had been implicated in Bcr-Abl
resistant to STI-571 (84,106,107). Phosphorylation of these sites may potentially
stabilize the active kinase conformation. Other phosphorylation sites may serve
as binding interface for SH2 containing proteins that may have regulatory role for
Abl kinases.

Abl family kinase activation as a multi-step process
Phosphorylation of Abl2 at Y439 (Y412 on Abl1) in the kinase activation loop is a
critical step for full kinase activation of Abl family kinases (26,48). However, how
this process is regulated is not fully understood. We show that PDGFRβ CD
phosphorylation on the Abl2 N-terminal half (Abl2N) promotes a 5.7-fold
activation over non-activated Abl2N in vitro. Mutation of Y116, Y161, Y272, Y310
and Y439 (5YF) abrogated PDGFRβ-mediated activation of Abl2 kinase activity.
Surprisingly, an Abl2N mutant in which Y439 was restored (e.g. the 4YF mutant Y116F, Y161F, Y272F and Y310F) could not undergo activation by PDGFRβ.
These data suggest either that Y439 is not efficiently phosphorylated when Abl
kinase remains in a “closed” inactive conformation or that Y439 phosphorylation
itself does not activate the kinase when the SH3 and SH2 domain remain in the
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auto-inhibited conformation. Our model may provide some insight that activation
loop phosphorylation and kinase activation may be regulated by N-terminal
domain conformation.
Future experiments are needed to quantify the extend of activation loop
phosphorylation under different Abl kinases conformations. Phosphorylation on
the SH3 and SH2-kinase linker may initiate the transformation of Abl kinases
from an auto-inhibited state to an extend state. This process may be required for
phosphorylation on the activation loop to function as it stabilized the active
kinase.
Our work adds to a growing body of data indicating that Abl kinases are not
simply switched between a closed auto-inhibited state and an open-active state
through a one-step process (9,25,26,29). Instead, Abl kinases appear to be
regulated by different types and degrees of intermolecular/ intramolecular
interactions and post-translational modifications across a spectrum of activity
levels (25-29). Our findings provide a mechanism to understand how Abl kinases
are precisely regulated through multi-steps phosphorylation events by receptor
tyrosine kinases.
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CHAPTER 3- PDGFR signaling regulate integrin
activation through Abl2
Abstract
Integrin adhesion receptors undergo rapid and reversible conformational
changes to regulate their affinity for extracellular ligands (91,108). This inside-out
signaling process, known as integrin activation, is achieved by binding of the
intracellular proteins talin and kindlin to the cytoplasmic tail of the integrin β
subunits (91,108). Regulated activation of integrin is critical for cell adhesion,
motility and tissue homeostasis (91,108). One understudied area of importance is
growth factor modulation of integrin signaling. A variety of growth factors
including PDGF, are known to modulate integrin signaling and activation (109114). However, the precise molecular mechanisms and signaling pathways
mediating growth factor regulation of integrins are as of yet not elucidated. Our
lab has demonstrated that β1-containing integrins signal through Abl2
nonreceptor tyrosine kinase (44,88,115). We recently showed that Abl2 is
activated through direct interaction with integrin β1 cytoplasmic tail. Interestingly,
the Abl2 binding interfaces on integrin β1 overlap with those of talin, a key
integrin activator (44). Hence, it is possible Abl2 may regulate talin-integrin
binding, and potentially act as an integrin inactivator. PDGFR can also directly
interact with Abl2 and activate its kinase activity, and my preliminary data
suggest that PDGFR may influence integrin activity through Abl2.
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Introduction
Integrins are a large family of transmembrane adhesion receptors that provide a
dynamic and bi-directional structural and signaling connection between the
extracellular matrix and intracellular cytoskeleton (91,108). Integrin receptors are
heterodimers comprised of α and β subunits, and they can shift between an
inactive bent conformation and an active extended conformation (91,108). The
binding of talin to the β integrin cytoplasmic tails induces conformational changes
of the integrin extracellular domain, which results in an increased affinity for
extracellular ligand binding (108,116-121). This process is known as integrin
activation, and it provides a rapid and reversible mechanism that regulates
integrin activity, which is crucial for cell adhesion, migration and differentiation
(108,116-121). Structural studies show that the talin F3 domain interacts with the
integrin β1 membrane proximal region through several key residues including two
phenylalanine and one tryptophan residue, as well as the membrane proximal
NPXY motif (118-121). Furthermore, talin binding to integrin β1 disrupts
interactions between the cytoplasmic membrane proximal regions of integrin α
and β, separating them and allowing them to interact with other intracellular
binding partners. This inside-out process also induces integrin receptors to adopt
an extended conformation leading to a higher affinity for extracellular matrix
ligands like fibronectin (108,116-121).
Competitive inhibition of talin binding to the integrin cytoplasmic domain provides
a common mechanism to regulate integrin activity (117,122-128). For example,
the immunoglobulin-like domain of filamin A directly interacts with the integrin β
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tail membrane proximal NPXY motif and competes away talin, which results in
inhibition of talin-dependent integrin activation (125). Tyrosine phosphorylation of
the integrin β tail is also a conserved mechanism for regulating integrin
activation. Studies show that the binding affinity between talin and integrin β3,
β1A, and β7 is greatly decreased by tyrosine phosphorylation (102,103). Our lab
recently showed that Abl2 kinase domain directly binds the lysine-rich region on
integrin β1 tail, and phosphorylates integrin β1 on the membrane proximal NPXY
motif (44). Interestingly, the binding interfaces on integrin β1 overlap with those
of talin (44). Abl2-mediated tyrosine phosphorylation on integrin β1 provides
additional binding site for Abl2 through its SH2 domain. Hence, Abl2 may inhibit
talin-dependent integrin activation through either direct competition in binding or
phosphorylation. There are extensive examples of cross-talk between growth
factor receptor and integrin (109-111,114,129,130). Emerging data from our lab
and others have shown that PDGF stimulation may have a role in regulating
integrin activation through Abl2. However, the role of Abl2 and the molecular
mechanism underlying the crosstalk between PDGFR and integrin remains
unknown. Here, I report initial studies that suggest Abl2 relays PDGFR signaling
to regulate integrin activation through inhibiting talin-integrin β1 interaction as this
model shows (Fig 3.1).

.
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Figure 3.1 Model of the molecular mechanism by which PDGFR signaling
regulate integrin activation through Abl2
PDGFR signaling activates Abl2 kinase, promotes Abl2-integrin β1interaction and
Abl2 mediated phosphorylation on integrin β1. This process competes away talin
for integrin binding and results in inhibition of talin-dependent integrin activation.
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Results

Abl2 competes with talin for integrin β1 interaction in cells upon PDGF
stimulation
To test whether Abl2 competes with talin for integrin β1 binding in cell, we used
Fluorescence Resonance Energy Transfer (FRET) by Fluorescence Lifetime
Imaging Microscopy (FLIM) to measure their interactions in collaboration with Dr.
Maddy Parsons. We found that FRET between Abl2 and β1 is robustly elevated
upon PDGF stimulation. Furthermore, this interaction is attenuated in cells
expressing β1 4KA (four lysine to alanine in the lysine rich motif, which
significantly reduces Abl2 binding) mutant (Fig 3.2A, B). Using similar methods,
we investigated the effect of PDGF stimulation on Abl2/talin competition in cells.
β1-/- mouse embryonic fibroblasts expressing β1-GFP and either talin-mRFP or
kindlin-mRFP in the presence or absence of Abl2-HA were stimulated with PDGF
(Fig 3.2C, D). FRET between β1 and either talin or kindlin were monitored using
FLIM. Kindlin is another integrin activator, but unlike talin, it engages the β tails
membrane distal NPxY/F motif whereas talin binds to the membrane proximal of
these motifs (131). We found that Abl2 overexpression led to a strong decrease
in FRET between β1 and talin, but not β1 and kindlin in response to PDGF
stimulation (Fig 3.2 C, D). Our data indicates that Abl2 specifically competes with
talin but not kindlin for β1 binding in cells. I also designed a small hairpin RNA
targeting Abl2 to knock down endogenous Abl2 expression levels (Fig 3.2 E).
Our results show that PDGF stimulation led to a significant reduction in FRET
between β1 and talin in control cells, but not in Abl2 knock down cells (Figs
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3.2E). Together, these data strongly suggest that Abl2 specifically competes with
talin for integrin β1 interaction in cells.

Figure 3.2 Abl2 competes with talin for integrin β1 interaction in fibroblast
(Figure caption on next page)
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Figure 3.2 Abl2 competes with talin for integrin β1 interaction in fibroblast
(A) β1-/- mouse embryonic fibroblasts (MEF) expressing Abl2-mCherry and
either β1-GFP or 4KA-β1-GFP were serum starved and then stimulated with
PDGF to monitor the ability of Abl2 to interact with β1 upon PDGF simulation.
PDGF enhances Abl2’s ability to interact with β1, but not the Abl2 kinase
interaction deficient β1 mutant, 4KA. (B) Quantification of FLIM-FRET from (A).
(C) β1-/- MEFs expressing β1-GFP and either talin-mRFP or kindlin-mRFP in the
presence or absence of Abl2-HA expression were either serum starved or
stimulated with PDGF before monitoring FRET by FLIM between β1 and either
talin or kindlin. Abl2 overexpression attenuates talin, but not kindlin, interactions
with β1 upon PDGF stimulation. (D) Quantification of FLIM-FRET from (C). (E)
(left panel) Quantification of FLIM-FRET of β1-/- MEFs either transfected with
control shRNA or Abl2 shRNA expressing β1-GFP and talin-mRFP were serum
starved and stimulated with PDGF before monitoring FRET by FLIM between β1
and talin. Western blot of MEFs untreated or transfected with control shRNA or
Abl2 shRNA probed for Abl2 (top) or GAPDH (bottom).
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PDGF stimulation promotes integrin β1Y783 phosphorylation by Abl2
Previous work from my former colleague Dr. Adam Simpson established that
Abl2 phosphorylates integrin β1 cytoplasmic domain on Y783. PDGF stimulation
not only activates Abl2 kinase, but also promotes Abl2-integrin β1 interaction in
cells. I hypothesized that PDGF simulation promotes integrin phosphorylation by
Abl2. To address this question, WT mouse 3T3 fibroblast cells were starved
overnight and treated with Mn2+ and PDGF, and lysates were blotted with a
phospho-specific antibody to pY783 in integrin β1. Mn2+ has been widely used to
simulate integrin activation in the absence of a bound ligand, potentially making
β1 cytoplasmic domain more accessible for cellular binding partners (132). My
results show that treatment of Mn2+ to activate integrins increases integrin β1
Y783 phosphorylation, which is consistent with previous findings (44). PDGF
stimulation after Mn2+ treatment leads to higher β1 Y783 phosphorylation levels
compared to Mn2+ treatment alone while integrin β1 expression levels remained
the same. (Fig 3.3A). To address whether Y783 phosphorylation is dependent on
Abl2 kinase activity, I transiently transfected HEK293 cells with YFP control,
Abl2-YFP and Abl2 (kinase inactive)-YFP, and measured integrin β1 Y783
phosphorylation following Mn2+ and PDGF treatment. My results show that Mn2+
and PDGF treatment led to a slight increase in integrin β1 phosphorylation in
YFP transfection control cells due to low endogenous Abl2 levels, whereas WT
Abl2 expression greatly increased β1 phosphorylation levels (Fig. 3.3B).
However, kinase inactive Abl2 expression does not increase Y783
phosphorylation level compared to YFP transfection control cells (Fig. 3.3B).
67

These results suggest that PDGF stimulation promotes Abl2 mediated integrin β1
Y783 phosphorylation.

Figure 3.3 PDGF stimulation promotes integrin β1 phosphorylation by Abl2
(A) WT mouse 3T3 fibroblast cells were serum starved overnight and treated with
2mM MnCl2 for one hour before stimulated with 100 ng/ml PDGF-BB for 10
minutes. 40 μg of lysate were immunoblotted with antibodies to integrin β1
pY783 and integrin β1. Ponceau S staining was used as loading control. Bottom
panel shows the quantification of normalized phosphotyrosine 783 intensity in
different conditions (n=4 for each condition, ** = p < 0.01). (2) HEK93 cells
expressing YFP control, Abl2-YFP or Abl2 (Kinase inactive)-YFP were serum
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starved overnight and treated with 2mM MnCl2 for one hour before stimulated
with 100 ng/ml PDGF-BB for 10 minutes. 40 μg of lysate were immunoblotted
with antibodies to integrin β1 pY783.

Abl2 and talin compete for integrin β1 binding in vitro
Previous work from our lab established that Abl2 directly engages integrin β1
cytoplasmic tail via two distinct interaction interfaces (44). The Abl2 kinase
domain directly interacts with a lysine-rich membrane-proximal segment in the
integrin β1 cytoplasmic tail, and it phosphorylates Y783 in the membrane
proximal NPxY motif of β1 (44). Abl2 SH2 domain can then engage the
phosphorylated NPxY motif in the integrin β1 tail (44). Given that these binding
interfaces overlap with those of talin, I hypothesized that Abl2 competes with talin
for binding to the integrin β1 tail (Fig 3.4A). To directly test this hypothesis, I
performed in vitro single competitor competition binding assay with talin F3
domain linked beads incubated with an increasing concentration gradient of
GST-β1 and either BSA or Abl2 N-terminal half (Abl2N) as competitor (Fig 3.4B).
GST-β1 tail retained on the talin F3 beads significantly reduced when Abl2N was
used as competitor compared to BSA (Fig 3.4B). This result indicates that Abl2
and talin compete for integrin β1 binding. Furthermore, I performed a similar
experiment with constant concentration of GST-β1 tail in the supernatant and an
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increasing concentration gradient of Abl2N as competitor (Fig 3.4C). The
increasing concentration gradient of Abl2N resulted in a dose dependent
decrease in β1 tail retaining on talin-linked beads, further validating that there is a
direct competition between Abl2 and talin for integrin β1 binding.
Note that the recombinant β1 tail is not phosphorylated in this experiment and
thus, talin F3 likely sterically blocks binding of Abl2 to the β1 lysine rich interface.
Abl2-mediated phosphorylation on the β1 NPxY motif would also influence the
competition between Abl2 and talin for binding to the β1 tail, both by potentially
increasing Abl2 affinity for the β1 tail, and by decreasing affinity of the β1 tail for
talin (102,103). Therefore, β1 phosphorylation may shift the Abl2/talin
competition equilibrium towards Abl2. To directly test whether integrin β1 Y783
phosphorylation affects Abl2 and talin interaction, I performed fluorescence
anisotropy (FA) binding assay with fluorescein isothiocyanate (FITC) tagged
Y783 phosphorylated and non-phosphorylated synthesized integrin β1 peptides.
The integrin β1 peptides (758D-787V) contain binding interfaces for both Abl2
and talin (Fig 3.4D). A constant concentration of FITC labeled β1 peptides were
titrated with an increasing concentration gradient of GST-Abl2 SH2 domain, talin
F3 domain, and GST as a control (Fig 3.4D). Protein-protein interaction
measured by change of FA between pY783 β1 peptide and Abl2 SH2 domain
reached saturation, while change of FA between GST/pY783 β1 and Abl2
SH2/non-phosphorylated β1 remained at low background level, as expected. To
ensure bona fide changes of FA resulting from protein-protein interactions, a
control competition experiment with untagged-pY783 β1 was performed (Fig
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3.4E). In this experiment, 5 nM of FITC-pY783 β1 was incubated with 5μM of
GST-Abl2SH2 and an increasing concentration gradient of unlabeled pY783 β1
peptide. The increasing concentration of unlabeled pY783 β1 peptide resulted in
a dose dependent decrease in FA, further validating that the change of FA
results from interaction between FITC-pY783 β1 and Abl2 SH2 domain. The
changes of FA between talin F3 domain and both pY783 β1 binding and
unphosphorylated β1 binding increases as talin F3 concentration increases, but
did not reach saturation (Fig 3.4D). There is no significant difference in binding
between pY783 β1 and unphosphorylated β1 binding to talin F3 domain.
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Figure 3.4 Abl2 and talin compete for integrin β1 binding
(A) Talin-β1 binding interface (blue) overlaps with Abl2 kinase and SH2 domain
binding interfaces (red and yellow). (B) 1μM of talin F3 domain linked beads were
incubated with 0-5 μM of GST-β1 integrin tail and 5 μM of either BSA or Abl2 Nterminal half as
competitor. (C) 1μM of talin F3 domain linked beads were incubated with 1 or 2
μM of GST-β1 integrin tail and a concentration gradient (0-5 μM) of Abl2N as
competitor. (D) (top panel) sequence of the FITC-tagged β1 peptide with the
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membrane proximal NPXY motif highlighted in red. One of the peptides is
phosphorylated on the NPXY tyrosine (Y783) (bottom panel) 5nM of FITC tagged
pY783 or non-phosphorylated β1 peptide were incubated with an increasing
concentration gradient of talinF3 domain, GST-Abl2SH2 domain and GST as a
control. Change of FA is measured and plotted against the concentration of
binding partners. (E) 5nM of FITC-pY783 β1 peptide was incubated with 5 μM of
Abl2 SH2 domain and an increasing concentration gradient of unlabeled pY783
β1. Change of FA is measured and plotted against unlabeled pY783 β1
concentration.

Investigate the effects of PDGF-driven Abl2 binding on integrin activity
Our FRET-FLIM data suggest that PDGF stimulation strongly reduces talin-β1
interaction through Abl2 signaling (Fig 3.2). Since talin is critical for integrin β1
activation, I hypothesized that PDGF stimulation may reduce the relative levels of
integrin α5β1 activation. In collaboration with Dr. Daniel Iwamoto in Dr. David
Calderwood’s lab, we assessed the activation state of endogenous α5β1 by
measuring the binding of a fibronectin fragment (FN9-11) to activated integrin in
a Fluorescence Activated Cell Sorting (FACS) based assay as previously
described (116,133). Briefly, after transfection or PDGF treatment, cells were
suspended and incubated with FN9-11, a soluble fibronectin fragment that binds
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to activated integrin α5β1. The activity of integrin in each experiment was
determined by activation index with the following equation:  ൌ ሺ െ
ͲሻȀሺ ሻ; where F is the mean fluorescence intensity (MFI) of FN 9-11
binding, and F0 is the MFI in presence of EDTA to prevent ligand binding. F
integrin is the normalized MFI of integrin antibody PB1 which determines total
surface integrin β1. We transfected Abl2 and talin (1-433) in CHO cells and
investigated how Abl2 and talin expression affects integrin activation. As
expected, talin (1-433) expression induced integrin activation, and high integrin
activity is correlated with high talin expression levels (Fig 3.5A). However, Abl2
expression does not affect integrin activation. We also transfected a small hairpin
RNA targeting Abl2 to knock down endogenous Abl2 expression levels. Abl2
knock down also did not have any significant effect on integrin activation (Fig
3.5A). Next, we tried to investigate whether PDGF stimulation affects integrin
activation through Abl2 signaling. WT or Abl2 knock out (KO) fibroblasts were
serum starved overnight and stimulated with different doses of PDGF (10ng/ml,
30ng/ml and 100ng/ml). Surprisingly, PDGF stimulation has no significant effect
on either WT or Abl2 KO fibroblast. Future experiments will be required to
investigate the biological importance of Abl2 mediated inhibition of talin-integrin
binding and identify if there are any additional players involved in this pathway.
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Figure 3.5 Abl2 expression or PDGF stimulation have no significant effect
on β1 integrin activation (Figure caption on next page)
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Figure 5.5 Abl2 expression or PDGF stimulation have no significant effect
on β1 integrin activation
(A) CHO cells were transfected with GFP-talin (1-433), GFP-Abl2, GFP-shAbl2
and GFP as transfection control. 24hour post-transfection, cells were detached,
washed and GFP expression and binding of FN-9-11 to live cells in the presence
or absence of EDTA were analyzed by FACS. α5β1 integrin expression was
assessed in parallel by staining with PB1. Integrin activation index was
determined with the following equation: AI=(F-F0)/ (F integrin); where F is the
mean fluorescence intensity (MFI) of FN 9-11 binding, and F0 is the MFI in
presence of EDTA to prevent ligand binding. F integrin is the normalized MFI of
integrin antibody PB1 which determines total surface integrin β1 (B) WT and Abl2
KO mouse fibroblasts were serum starved overnight and stimulated with different
dose of PDGF for 10 minutes Cells were detached, washed and the activation
index of endogenous α5β1 integrin was assessed as described in (A).
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Discussion and future direction.
Here I report a putative molecular mechanism by which PDGFR signaling
regulates integrin activation through Abl2-mediated inhibition of talin-integrin β1
interaction. This could be achieved through either talin-Abl2 direct binding
competition or integrin β1 Y783 phosphorylation by Abl2. Direct binding
competition and phosphorylation events are common mechanisms to regulate
integrin activity by many integrin inhibitors (102,103,122-124). My initial findings
suggest thsat PDGF simulation promote Abl2-integrin β1 interaction and β1 Y783
phosphorylation by Abl2. PDGF stimulation also significantly reduces integrin
β1/talin interaction, and the reduction is directly related to Abl2 expression level.
Inhibition of talin-integrin β1 interaction by other integrin inhibitors regulates
integrin activation, which is crucial for proper cell migration and adhesion. Abl2
acting downstream of PDGFR to regulate integrin activation may provide a
mechanism to allow PDGFR to crosstalk with integrin to regulate cancer
metastasis, angiogenesis and embryonic development (110,134-136). My initial
findings demonstrate that there are more players and factors involved in the
downstream PDGFR stimulation-mediated Abl2 regulation, leaving many doors
open for future studies to further dissect this complex signaling pathway.
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What is the role of Abl2 mediated integrin phosphorylation on talin-integrin
interaction?
We found that Abl2 overexpression led to a strong decrease in interaction
between β1 and talin upon PDGF stimulation. However, whether the disruption of
talin-integrin β1 binding is mediated through Abl2 binding and/or phosphorylation
is not known. Using Abl kinases specific inhibitors like GNF-2 or GNF-5 in FRETFLIM experiments to investigate whether Abl2, with its kinase activity inhibited,
can disrupt talin-integrin β1 interaction remains unexplored. Using Abl2 KO
fibroblasts rescued with kinase inactive Abl2 (K317M) will also be useful to
evaluate the importance of Abl kinases activity in disrupting talin-integrin
interaction. Previous studies show that talin F3 domain engages the integrin β1
tail through several key residues, but the membrane proximal NPXY motif is
particularly important. Phosphorylation of NPXY tyrosine inhibits talin binding
(102,103). A single tyrosine to alanine mutation in the β1 NPXY motif prevents
talin binding and affects cell adhesion, spreading, and migration.
(103,121,133,137,138) Mice bearing this mutation result in β1 null-like periimplantation lethality (138). Therefore, it is expected that Abl2 mediated
phosphorylation of β1 membrane proximal NPXY Tyr783 would inhibit talin
binding.
I used chemically synthesized nonphosphorylated and pY783 integrin β1 peptide
in fluorescence anisotropy (FA) experiments to test the effect of Y783
phosphorylation in talin binding. Based on my FA measurements, the
dissociation constants (KD) of talin- β1A interaction is high (approximately 450
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μM, though estimation may not be accurate since as the binding curve did not
reach saturation). This result conflicts with some previous studies that reported
KD of talin-β1A interaction to be less than 100 nM using surface plasmon
resonance and pulldown assays (133,139). However, solution NMR was used in
some studies to estimate the KD of talin-β1A interaction to be ~500 μM
(103,121,140). The variability of affinities may arise from different technologies,
different talin fragments, differences in β integrin sequence used, different buffer
condition and sample preparations. For example, one structure study suggests
that β1D, a splice variant from β1A, binds talin with higher affinity (over 10 fold)
due to two amino acids difference in sequence (140). However, despite the big
discrepancies in affinity measurements, these studies suggest that NPXY
tyrosine mutation or phosphorylation greatly affect talin binding. Aside from
inhibiting talin binding, Abl2 mediated phosphorylation of β1 membrane proximal
NPXY Tyr783 may also promote the binding of other integrin inhibitor like
Dok1(102). Further experiments are required to determine the role of Abl2
mediated phosphorylation of integrin β1 on talin binding.

What is the biological importance of Abl2 mediated inhibition of talinintegrin binding?
Integrin activation by talin is essential for normal development because it
regulates cell adhesion and migration, and connects the extracellular matrix with
the intracellular cytoskeleton (108,116,133,139). Loss of ubiquitously expressed
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integrin β1 or talin1 results in embryonic lethality (128). However, integrin
inactivating proteins are also crucial for regulating integrin function and finetuning
the balance between integrin activation and inactivation during many cellular
processes (122-128). The most common mechanism of integrin inactivation
involves binding of integrin inactivators to the integrin cytoplasmic tail, and inhibit
the binding of integrin activator such as talin (122-128). Upon PDGF stimulation,
Abl2 binds to integrin β1 cytoplasmic tail, and inhibits talin biding. Therefore, it is
expected that Abl2 mediated inhibition of talin-integrin binding upon PDGF
stimulation would result in integrin inactivation.
We assessed the activation state of integrin α5β1 by mearing the binding of
fibronectin fragment to activated integrin in FACS based assay. Results show
that there is no significant effect on integrin activation after PDGF stimulation or
change of Abl2 expression level. Even though it is unexpected, this result can be
explained with the following postulations: FRET-FLIM results demonstrated that
there is only a very small decrease of FRET between talin in integrin β1 after
Abl2 overexpression. The reduction of FRET is only substantial after PDGF
stimulation (Fig 3.2D). Therefore, it is possible that overexpression of Abl2 in its
inactivated form will not be able to affect talin-integrin binding. The observation
that overexpression of Abl2 alone did not result in high level of integrin Y783
phosphorylation (Fig 3.3B) is consistent with this hypothesis. My integrin
activation assay showed that PDGF stimulation did not result in any significant
changes of integrin activity (Fig 3.5B) likely due to the time-sensitive nature of
PDGF stimulation. Tyrosine phosphorylation level of PDGFR peaked at ~10
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minutes post-PDGF stimulation, and quickly diminished due to PDGFR down
regulation, a phenomenon usually involved in ligand induced receptor
internalization, ubiquitin-mediated proteolysis, and dephosphorylation by
phosphotyrosine phosphatase (141-143). PDGF-mediated activation of
phosphatidylinositol 3 kinase (PI3K) also peaked at ~10 minutes and diminished
to basal levels at ~30 minutes (144). Therefore, it is possible that the effect of
PDGFR/Abl2-mediated inhibition of talin-integrin interaction is not sustained
when the integrin activation assay was performed. The FACS based integrin
activation assay is limited by its long preparation time. If possible, using real-time
microscopy to assess integrin activation after PDGF stimulation will be more
informative.
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CHAPTER 4- MATERIALS AND METHODS

Molecular Cloning and Recombinant Protein Purification
Full-length Abl2 (residues 74-1182), Abl2 N-terminus (residue 74-557), Abl2
kinase domain (residue 288-539) and PDGFRβ cytoplasmic domain (residues
554-1106) were cloned with a N-terminal 6XHis tag into the pFastBac1 vector
(Invitrogen), as previously described (9). Abl2 C-terminus (residue 557-1182)
was cloned with an N-terminal maltose binding protein (MBP) tag into the
pFastBac1 vector (Invitrogen), as previously described (35). All Abl2 and
PDGFRβ point mutants were generated using PCR-based mutagenesis and
confirmed by DNA sequencing. Recombinant baculoviruses expressing these
constructs were generated using the Bac-to-Bac expression system (Thermo
Fisher) in Sf9 insect cells, as described previously (9). After expression in Hi5
insect cells for 48 h, cells were lysed in Hi5 lysis buffer (50 mM Hepes pH 7.25,
150 mM NaCl, 5% glycerol, 20 mM imidazole, 1 mM DTT, and protease inhibitors
(benzamidine, aprotinin, leupeptin, chymostatin, pepstatin A, and
phenylmethylsulfonyl fluoride)). All 6XHis-tagged proteins were affinity-purified on
nitrilotriacetic acid resin (Qiagen) and eluted with 250 mM imidazole. Proteins
were further purified by S200 gel filtration chromatography. MBP-tagged proteins
were affinity purified on amylose resin (New England Biolabs), eluted with 10 mM
maltose and further purified by S200 gel filtration chromatography. All proteins
were buffer-exchanged into assay buffer containing 50 mM Hepes pH 7.25, 150
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mM NaCl, 5% glycerol, and 1 mM DTT using 10 ml columns packed with
Sephadex G25 resin.
The Abl2 SH3-SH2 and SH2 domains were cloned in frame with GST into the
pGEX-6P-1 vector and GST-Abl2-SH3-SH2 and GST-Abl2-SH2 fusion proteins
were purified from BL21 (DE3) E. coli cells (Millipore Sigma) on glutathione 4B
beads (GE Healthcare). The GST tags were cleaved using PreScission protease
(GE Healthcare), as previously described (9). GST-CrkII was cloned into pGEX4T-1 and purified from E. coli on glutathione 4B beads (GE Healthcare), as
previously described (26). Before use in assays, all proteins were bufferexchanged into assay buffer containing 50 mM Hepes pH 7.25, 150 mM NaCl,
5% glycerol and 1 mM DTT 10 ml columns packed with Sephadex G25 resin.
Cross-linking of Recombinant Proteins to Beads
minoLink (Thermo Scientific) beads were used to covalently link Abl2 SH2
domain following purification (9). Briefly, proteins were gently rotated with
AminoLink beads overnight. 50 mM Sodium cyanoborohydride was added to
catalyze the reaction. Protein was linked at a final reaction concentration of 1 μM,
and the remaining reactive sites on protein-linked beads were blocked with 1 M
Tris-HCl, pH 8.0 and 100 mg/ml BSA, washed, and stored in assay buffer.
Binding Assays
Binding assays were conducted as previously described (44). For determination
of the PDGFRβ cytoplasmic domain (CD)-Abl2 SH2 domain binding interface,
purified Abl2 SH2 and SH2 (R198K) were covalently linked to AminoLink beads
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as described above and added to binding reactions at a final concentration of 1
μM. For determination of Kd values, an increasing concentration gradient of
PDGFRβ CD constructs from 0 to 2 μM were used. Binding reactions were
incubated for 1 h at 4°C before washing and resuspending in Laemmli sample
buffer (LSB). Bead-associated material were boiled and separated on SDS
PAGE gels. Gel bands were resolved with Coomassie Blue Silver stain and
densities were quantified using Image J (NIH) (145). For measurements of K,
band densities were plotted against concentration of the free solution protein,
and binding isotherms were set using GraphPad software using the one-site
specific binding equationǡ ܻ ൌ  ܤ௫ ܺ כȀሺܭௗ  ܺሻ, where Y is specific binding, X
is the concentration of the ligand, Bmax is the maximum specific binding, in the
same units as Y, and Kd is the binding affinity in the same units as X.

In Vitro Kinase Assays
Kinase assays were performed by preincubating 5 nM PDGFRβ CD and 0-2 μM
Abl2 constructs in 50 mM Hepes pH 7.25, 150 mM NaCl, 5% glycerol, 5 mM
MgCl2, 5 mM MnCl2, 1 mM sodium pervanadate, 1 mM DTT for 5 min at 32°C
before initiating reactions with 5 μM ATP with 0.75 μCi of [γ-32P]ATP for 10 min
before terminating with LSB, running on gels, and exposing to a
phosphorimaging screen. Screens were scanned using a Personal Molecular
Imager (Bio-Rad), and band densities were quantified using ImageJ software
(145).
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For in vitro Abl2 activation experiments, 1 μM purified recombinant Abl2
constructs were preincubated with 1 nM PDGFRβ CD for 2 hours at 32°C in 25
mM Hepes pH 7.25, 100 mM NaCl, 5% glycerol, 5 mM MgCl 2, 5 mM MnCl2, 1
mM sodium pervanadate, 1 mM DTT and 10 μM cold ATP. After 2 hours
preincubation on ice, 25 μl reactions were initiated by addition of GST-CrkII (0-16
μM as substrate), 1 nM of preincubated Abl2 kinase proteins, 5 μM ATP, and 0.5
μCi of [γ-32P] ATP. All reactions were quenched with 1X LSB after 10 mins,
boiled, and separated on 10% SDS PAGE gels. Gels were stained with Blue
Silver G-250 Coomassie for 30 min to visualize GST-CrkII protein bands. Bands
were cut out, along with background regions within the same lane and
scintillation counted along with a 1 μL sample from the kinase assay. The
number of counts per minute was calculated and KM and kcat values were
determined as previously (44,46).
Cell culture, construct transfection and Antibody
Experiments were performed in HEK293 cells (ATCC, Manassas, VA) and
mycoplasma free WT mouse 3T3 fibroblast cells. Cells were grown in Dulbecco’s
Modified Eagle’s Medium supplemented with 10% FBS, 100 units/ml penicillin,
100 μg/ml streptomycin, and 2 mM L-glutamine. abl2−/− and abl1−/−abl2−/− 3T3
fibroblasts were generated using CRISPR/Cas9. A guide sequence of 5’CATGTAAAGTAACACGACGG-3’ with an adjacent protospacer adjacent motif,
PAM (CGG) targeting the seventh exon of Abl2 was inserted into lentiCRISPRv2
plasmid (Addgene Plasmid #52961), then transfected into HEK293T cells to
generate Abl2sg1 lentivirus. WT mouse 3T3 fibroblast cells were infected with
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the generated Abl2sg1 lentivirus then selected with 2 μg/ml puromycin for 72 h to
generate abl2−/− 3T3 cells. Another guide sequence of 5’GTTAGTTCACCATCACTCCA-3’ with an adjacent protospacer adjacent motif,
PAM (CGG) targeting the fourth exon of Abl1 was inserted into lentiCRISPRv2
neo plasmid (Addgene Plasmid #98292), then transfected into HEK293T cells to
generate Abl1sg1 lentivirus. WT mouse 3T3 fibroblast cells were infected with
the generated Abl2sg1 lentivirus and Abl1sg1 lentivirus simultaneously then
selected with 2 μg/ml puromycin and 800 μg/ml G418 to generate abl1−/−abl2−/−
DKO 3T3 cells.
The following antibodies were used for this study: phosphotyrosine (4G10;
Upstate/Millipore, Billerica, MA, or affinity-purified from hybridomas), (P)-Y751
PDGFRβ (Cell Signaling, Danvers, MA), CrkII (Cell Signaling, Danvers, MA), (P)Y221 CrkII (Cell Signaling, Danvers, MA), Abl2 (Ar11, Ar19; purified from
hybridomas), HA (12CA5 purified from hybridomas), PY (4G10 purified from
hybridomas), PR4, a rabbit polyclonal antiserum recognizing the C-terminal 13
amino acids of the human PDGFRβ was a generous gift from Daniel DiMaio
(Yale University, New Haven, CT)
In vivo PDGFRβ pulldown binding assay
HEK293 cells were transiently transfected with WT or mutant full length PDGFRβ
using polyethylenimine transfection. 48 h after transfection, cells were serum
starved overnight with DMEM only medium. PDGFRβ was then stimulated with
100 nM of PDGF-BB for 10 mins. Cells were lysed in RIPA buffer (50mM Hepes,
pH7.25, 150 mM NaCl,1% Nonidet P-40, 1 mM EDTA, 1% deoxycholic acid,
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0.1% SDS, 0.5 mM sodium pervanadate and protease inhibitor). 500 μg of lysate
were incubated with 1 μM of Abl2 SH2-linked beads in a 500 μl reaction
overnight before washing and resuspending in LSB. Pulldown products were
boiled, separated by SDS-PAGE, transferred, and then immunoblotted for
PDGFRβ.
Immunoprecipitation
Abl2-HA was immunoprecipitated from HEK298 cells lysed in Triton lysis buffer
(25 mM Hepes, pH 7.25, 150 mM NaCl, 1 mM EDTA,10% glycerol, 1% Triton X100 0.5 mM sodium pervanadate and protease inhibitor). Cell lysate (0.5 mg;
standardized to 1 mg/ml) was precleared with 20 μl of Protein A/G Plus Agarose
bead (Thermo Scientific) for 1 hour at 4°C. The precleared supernatant was
incubated with 20 μl of beads that had been incubated overnight with anti-HA
antibody (12CA5) for 1 h at 4°C. Immunoprecipitates were washed three times
with 0.5 ml of lysis buffer, suspended in 40 μl of LSB, and separated by SDSPAGE for immunoblot analysis.
Measurement of CrkII phosphorylation
WT and abl1−/−abl2−/− DKO KO mouse 3T3 fibroblast were serum starved
overnight before stimulation with 100 nM of PDGF-BB for 10 mins. Cells were
lysed in RIPA buffer (50mM Hepes, pH 7.25, 150 mM NaCl,1% Nonidet P-40, 1
mM EDTA, 1% deoxycholic acid, 0.1% SDS, 0.5mM sodium pervanadate and
protease inhibitor). 40 μg of lysate and 10 μl of Laemmli sample buffer (LSB)
were boiled, separated by on SDS-PAGE, transferred, and then blotted for CrkII,
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(P)-Y221 CrkII, PDGFRβ, (P)-Y751 PDGFRβ. 500 μg of cell lysate were
precleared with A/G-agarose beads (Pierce Protein Biology) and incubated
overnight at 4°C with Ar11 antibody beads to immunoprecipitate Abl2.
Immunocomplexes were incubated with protein A/G-agarose beads for 1 h at 4°C
before spinning down, washing and resuspending in LSB). Pull down products
were boiled, separated by SDS-PAGE, transferred, and then immunoblotted for
Abl2 and phospho-tyrosine.
In Solution Proteolysis and Phosphopeptide Enrichment
In vitro phosphorylated Abl2 (50 mg) was reduced with DTT (10 mM, 30 min,
56°C), alkylated with iodoacetamide (IAM, 30 mM, room temperature, 45 min in
dark) and then digested with trypsin in a trypsin to protein ratio of 1:20 at 37°C
overnight. The reaction was quenched by 1% formic acid (FA, final
concentration). The resulting peptides were dried using a SpeedVac (Thermo,
SPD1010), desalted with PierceTM C18 tips (Thermo), and the phosphopeptides
were enriched by TitansphereTM Phos-TiO Kit (GL Science) according to the
manufacturer's protocol.
LC-MS/MS Analysis
The enriched phosphopeptides were analyzed by mass spectrometry (MS) using
a Dionex Ultimate 3000 nano-UHPLC system LC coupled with a Thermo
Scientific Orbitrap Velos Pro mass spectrometer. The Dionex Ultimate 3000
system was equipped with an Acclaim PepMap 100 (C18, 5 μm, 100 Å, 100 μm x
2 cm, Thermo Scientific, Waltham, MA) trap column and an Acclaim PepMap
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RSLC (C18, 2 μm, 100 Å, 75 μm x 50 cm, Thermo Scientific, Waltham, MA)
analytical column. The phosphopeptides were separated using the following
chromatography conditions: flow rate 300 nL/min, mobile phase A: 95% H 2O, 5%
acetonitrile (ACN), and 0.1% FA; mobile phase B: 20% H 2O, 80% ACN, and
0.1% FA; and, linear gradient starting at 5% B at 0 min to 40% B at 105 min. The
MS spray voltage was set in 2.1 kV, temperature of the heated capillary was
200°C. The MS analysis was performed using a top-10 data dependent analysis
in the positive ion mode with dynamc exclusion option enabled for 30 sec.
MS/MS spectra were collected using high-energy collisional dissociation (HCD)
and the overall method was setup in XCalibur 2.1 software (Thermo Scientific,
Waltham, MA). Raw MS and MS/MS data were then searched against a custom
made database which included the sequence of recombinant Abl2 in the
background of E. coli database, using Sequest HT algorithm within the Proteome
Discoverer v2.2 (Thermo Scientific) and with the following parameters: parent
mass error tolerance, 10 ppm; fragment mass error tolerance, 0.6 Da
(monoisotopic); maximum missed cleavage sites, 2; variable modifications:
+15.995 Da (oxidation) on methionine, and +79.996 Da (phosphorylation) on
serine, threonine, and tyrosine; fixed modification: +57.021 Da
(carbamidomethylation) on cysteine.
FRET-FLIM studies
FRET-FLIM studies were performed by Dr. Maddy Parsons as described in
(146). β1-/- MEFs were transfected with β1-GFP WT or mutant constructs and
Abl2 mRFP for binding studies, or β1-GFP WT and talin-RFP or kindlin-RFP, with
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or without Arg-HA DNA for competition assays. Cells were serum starved and
then treated with 30 ng/mL PDGF for 10 mins before fixing, staining, and
imaging.
Integrin activation assay
The activation state of endogenous α5β1 was assessed by measuring the
binding of a recombinant soluble integrin-binding fragment of fibronectin (FN9–
11) in flow cytometric assays as described in (133). In experiments on CHO cells
the α5β1 integrin expression was assessed in parallel by staining with PB1.
Briefly, CHO were transfected with the indicated cDNAs using Lipofectamine
(Invitrogen) and 24 h later cells were suspended and incubated with biotinylated
recombinant FN9–11 in the presence or absence of integrin activators or
inhibitors. Cells were washed and bound FN9–11 was detected with APCconjugated streptavidin. FN9–11 binding was assessed on a FACSCalibur
instrument (BD Biosciences).

Reference

1.
2.

3.

Abelson, H. T., and Rabstein, L. S. (1970) Influence of prednisolone on Moloney
leukemogenic virus in BALB-c mice. Cancer Res 30, 2208-2212
Goff, S. P., Gilboa, E., Witte, O. N., and Baltimore, D. (1980) Structure of the Abelson
murine leukemia virus genome and the homologous cellular gene: studies with cloned
viral DNA. Cell 22, 777-785
Ben-Neriah, Y., Daley, G. Q., Mes-Masson, A. M., Witte, O. N., and Baltimore, D. (1986)
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl
hybrid gene. Science 233, 212-214
90

4.
5.
6.
7.

8.
9.
10.
11.
12.

13.

14.
15.
16.
17.
18.

19.

20.
21.
22.
23.
24.

Srinivasan, D., and Plattner, R. (2006) Activation of Abl tyrosine kinases promotes
invasion of aggressive breast cancer cells. Cancer Research 66, 5648-5655
Ganguly, S. S., and Plattner, R. (2012) Activation of abl family kinases in solid tumors.
Genes Cancer 3, 414-425
Khatri, A., Wang, J., and Pendergast, A. M. (2016) Multifunctional Abl kinases in health
and disease. Journal of Cell Science 129, 9-16
Mader, C. C., Oser, M., Magalhaes, M. A., Bravo-Cordero, J. J., Condeelis, J., Koleske, A.
J., and Gil-Henn, H. (2011) An EGFR-Src-Arg-cortactin pathway mediates functional
maturation of invadopodia and breast cancer cell invasion. Cancer Res 71, 1730-1741
Moresco, E. M., and Koleske, A. J. (2003) Regulation of neuronal morphogenesis and
synaptic function by Abl family kinases. Curr Opin Neurobiol 13, 535-544
Schlatterer, S. D., Acker, C. M., and Davies, P. (2011) c-Abl in neurodegenerative disease.
J Mol Neurosci 45, 445-452
Backert, S., Feller, S. M., and Wessler, S. (2008) Emerging roles of Abl family tyrosine
kinases in microbial pathogenesis. Trends Biochem Sci 33, 80-90
Wessler, S., and Backert, S. (2011) Abl family of tyrosine kinases and microbial
pathogenesis. Int Rev Cell Mol Biol 286, 271-300
Wetzel, D. M., Rhodes, E. L., Li, S., McMahon-Pratt, D., and Koleske, A. J. (2016) The Src
kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and
Leishmania infection. J Cell Sci 129, 3130-3143
Koleske, A. J., Gifford, A. M., Scott, M. L., Nee, M., Bronson, R. T., Miczek, K. A., and
Baltimore, D. (1998) Essential roles for the Abl and Arg tyrosine kinases in neurulation.
Neuron 21, 1259-1272
Zipfel, P. A., Zhang, W. G., Quiroz, M., and Pendergast, A. M. (2004) Requirement for Abl
kinases in T cell receptor signaling. Curr Biol 14, 1222-1231
Tanos, B., and Pendergast, A. M. (2006) Abl tyrosine kinase regulates endocytosis of the
epidermal growth factor receptor. J Biol Chem 281, 32714-32723
Tanos, B. E., and Pendergast, A. M. (2007) Abi-1 forms an epidermal growth factorinducible complex with Cbl: role in receptor endocytosis. Cell Signal 19, 1602-1609
Jacob, M., Todd, L. A., Majumdar, R. S., Li, Y., Yamamoto, K., and Pure, E. (2009)
Endogenous cAbl regulates receptor endocytosis. Cell Signal 21, 1308-1316
Lapetina, S., Mader, C. C., Machida, K., Mayer, B. J., and Koleske, A. J. (2009) Arg
interacts with cortactin to promote adhesion-dependent cell edge protrusion. J Cell Biol
185, 503-519
Peacock, J. G., Couch, B. A., and Koleske, A. J. (2010) The Abl and Arg Non-receptor
Tyrosine Kinases Regulate Different Zones of Stress Fiber, Focal Adhesion, and
Contractile Network Localization in Spreading Fibroblasts. Cytoskeleton 67, 666-675
Qiu, Z. Z., Cang, Y., and Goff, S. P. (2010) c-Abl tyrosine kinase regulates cardiac growth
and development. P Natl Acad Sci USA 107, 1136-1141
Maiani, E., Diederich, M., and Gonfloni, S. (2011) DNA damage response: the emerging
role of c-Abl as a regulatory switch? Biochem Pharmacol 82, 1269-1276
Meltser, V., Ben-Yehoyada, M., and Shaul, Y. (2011) c-Abl tyrosine kinase in the DNA
damage response: cell death and more. Cell Death Differ 18, 2-4
Greuber, E. K., Smith-Pearson, P., Wang, J., and Pendergast, A. M. (2013) Role of ABL
family kinases in cancer: from leukaemia to solid tumours. Nat Rev Cancer 13, 559-571
Colicelli, J. (2010) ABL tyrosine kinases: evolution of function, regulation, and specificity.
Sci Signal 3, re6

91

25.

26.

27.

28.
29.

30.
31.

32.
33.
34.
35.

36.

37.
38.

39.

40.

41.

42.

Bradley, W. D., and Koleske, A. J. (2009) Regulation of cell migration and morphogenesis
by Abl-family kinases: emerging mechanisms and physiological contexts. Journal of Cell
Science 122, 3441-3454
Kruh, G. D., Perego, R., Miki, T., and Aaronson, S. A. (1990) The complete coding
sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases. Proc Natl
Acad Sci U S A 87, 5802-5806
Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, V., Clarkson,
B., Superti-Furga, G., and Kuriyan, J. (2003) Structural basis for the autoinhibition of cAbl tyrosine kinase. Cell 112, 859-871
David-Cordonnier, M. H., Hamdane, M., Bailly, C., and D'Halluin, J. C. (1998)
Determination of the human c-Abl consensus DNA binding site. FEBS Lett 424, 177-182
Miller, A. L., Wang, Y., Mooseker, M. S., and Koleske, A. J. (2004) The Abl-related gene
(Arg) requires its F-actin-microtubule cross-linking activity to regulate lamellipodial
dynamics during fibroblast adhesion. J Cell Biol 165, 407-419
Hu, Y. H., Lyu, W. Q., Lowery, L. A., and Koleske, A. J. (2019) Regulation of MT dynamics
via direct binding of an Abl family kinase. J Cell Biol 218, 3986-3997
Zhang, K., Lyu, W. Q., Yu, J., and Koleske, A. J. (2018) Abl2 is recruited to ventral actin
waves through cytoskeletal interactions to promote lamellipodium extension. Mol Biol
Cell 29, 2863-2873
Cicchetti, P., Mayer, B., Thiel, G., and Baltimore, D. (1992) Identification of a protein that
binds to the SH3 region of Abl and is similar to Bcr and GAP-rho. Science 257, 803-806
Mayer, B. J., and Baltimore, D. (1994) Mutagenic analysis of the roles of SH2 and SH3
domains in regulation of the Abl tyrosine kinase. Mol Cell Biol 14, 2883-2894
Barila, D., and Superti-Furga, G. (1998) An intramolecular SH3-domain interaction
regulates c-Abl activity. Nat Genet 18, 280-282
Pisabarro, M. T., Serrano, L., and Wilmanns, M. (1998) Crystal structure of the abl-SH3
domain complexed with a designed high-affinity peptide ligand: implications for SH3ligand interactions. J Mol Biol 281, 513-521
Musacchio, A., Saraste, M., and Wilmanns, M. (1994) High-Resolution Crystal-Structures
of Tyrosine Kinase Sh3 Domains Complexed with Proline-Rich Peptides. Nat Struct Biol 1,
546-551
Pendergast, A. M. (2002) The Abl family kinases: Mechanisms of regulation and
signaling. Adv Cancer Res 85, 51-100
Wagner, M. J., Stacey, M. M., Liu, B. A., and Pawson, T. (2013) Molecular Mechanisms of
SH2-and PTB-Domain-Containing Proteins in Receptor Tyrosine Kinase Signaling. Csh
Perspect Biol 5
Liu, B. A., and Machida, K. (2017) Introduction: History of SH2 Domains and Their
Applications. in SH2 Domains: Methods and Protocols (Machida, K., and Liu, B. A. eds.),
Springer New York, New York, NY. pp 3-35
Songyang, Z., Shoelson, S. E., Chaudhuri, M., Gish, G., Pawson, T., Haser, W. G., King, F.,
Roberts, T., Ratnofsky, S., Lechleider, R. J., and et al. (1993) SH2 domains recognize
specific phosphopeptide sequences. Cell 72, 767-778
Tinti, M., Kiemer, L., Costa, S., Miller, M. L., Sacco, F., Olsen, J. V., Carducci, M., Paoluzi,
S., Langone, F., Workman, C. T., Blom, N., Machida, K., Thompson, C. M., Schutkowski,
M., Brunak, S., Mann, M., Mayer, B. J., Castagnoli, L., and Cesareni, G. (2013) The SH2
domain interaction landscape. Cell Rep 3, 1293-1305
Gifford, S. M., Liu, W. Z., Mader, C. C., Halo, T. L., Machida, K., Boggon, T. J., and Koleske,
A. J. (2014) Two Amino Acid Residues Confer Different Binding Affinities of Abelson
92

43.

44.

45.

46.

47.

48.

49.

50.

51.
52.

53.
54.
55.

56.

57.
58.

Family Kinase Src Homology 2 Domains for Phosphorylated Cortactin. Journal of
Biological Chemistry 289, 19704-19713
Hantschel, O., and Superti-Furga, G. (2006) Mechanisms of Activation of Abl Family
Kinases. in Abl Family Kinases in Development and Disease, Springer New York, New
York, NY. pp 1-10
Simpson, M. A., Bradley, W. D., Harburger, D., Parsons, M., Calderwood, D. A., and
Koleske, A. J. (2015) Direct interactions with the integrin beta1 cytoplasmic tail activate
the Abl2/Arg kinase. J Biol Chem 290, 8360-8372
Brasher, B. B., and Van Etten, R. A. (2000) c-Abl has high intrinsic tyrosine kinase activity
that is stimulated by mutation of the Src homology 3 domain and by
autophosphorylation at two distinct regulatory tyrosines. J Biol Chem 275, 35631-35637
Tanis, K. Q., Veach, D., Duewel, H. S., Bornmann, W. G., and Koleske, A. J. (2003) Two
distinct phosphorylation pathways have additive effects on Abl family kinase activation.
Mol Cell Biol 23, 3884-3896
Plattner, R., Koleske, A. J., Kazlauskas, A., and Pendergast, A. M. (2004) Bidirectional
signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol
Cell Biol 24, 2573-2583
Boyle, S. N., Michaud, G. A., Schweitzer, B., Predki, P. F., and Koleske, A. J. (2007) A
critical role for cortactin phosphorylation by Abl-family kinases in PDGF-induced dorsalwave formation. Curr Biol 17, 445-451
Kain, K. H., and Klemke, R. L. (2001) Inhibition of cell migration by Abl family tyrosine
kinases through uncoupling of Crk-CAS complexes. Journal of Biological Chemistry 276,
16185-16192
Hernandez, S. E., Settleman, J., and Koleske, A. J. (2004) Adhesion-dependent regulation
of p190RhoGAP in the developing brain by the Abl-related gene tyrosine kinase. Curr
Biol 14, 691-696
Wong, S., and Witte, O. N. (2004) The BCR-ABL story: Bench to bedside and back. Annu
Rev Immunol 22, 247-306
Ganguly, S. S., Fiore, L. S., Sims, J. T., Friend, J. W., Srinivasan, D., Thacker, M. A., Cibull,
M. L., Wang, C., Novak, M., Kaetzel, D. M., and Plattner, R. (2012) c-Abl and Arg are
activated in human primary melanomas, promote melanoma cell invasion via distinct
pathways, and drive metastatic progression. Oncogene 31, 1804-1816
Advani, A. S., and Pendergast, A. M. (2002) Bcr-Abl variants: biological and clinical
aspects. Leuk Res 26, 713-720
Hantschel, O. (2012) Structure, regulation, signaling, and targeting of abl kinases in
cancer. Genes Cancer 3, 436-446
Lugo, T. G., Pendergast, A. M., Muller, A. J., and Witte, O. N. (1990) Tyrosine kinase
activity and transformation potency of bcr-abl oncogene products. Science 247, 10791082
Salesse, S., and Verfaillie, C. M. (2002) BCR/ABL: from molecular mechanisms of
leukemia induction to treatment of chronic myelogenous leukemia. Oncogene 21, 85478559
Smith, K. M., Yacobi, R., and Van Etten, R. A. (2003) Autoinhibition of Bcr-Abl through Its
SH3 Domain. Mol Cell 12, 27-37
Mcwhirter, J. R., Galasso, D. L., and Wang, J. Y. J. (1993) A Coiled-Coil Oligomerization
Domain of Bcr Is Essential for the Transforming Function of Bcr-Abl Oncoproteins. Mol
Cell Biol 13, 7587-7595

93

59.

60.

61.
62.

63.

64.

65.
66.
67.

68.
69.

70.
71.

72.
73.

74.
75.

Beissert, T., Hundertmark, A., Kaburova, V., Travaglini, L., Mian, A. A., Nervi, C., and
Ruthardt, M. (2008) Targeting of the N-terminal coiled coil oligomerization interface by
a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL. Int J Cancer 122,
2744-2752
Mian, A. A., Oancea, C., Zhao, Z., Ottmann, O. G., and Ruthardt, M. (2009)
Oligomerization inhibition, combined with allosteric inhibition, abrogates the
transformation potential of T315I-positive BCR/ABL. Leukemia 23, 2242-2247
Garcia-Gutierrez, V., and Hernandez-Boluda, J. C. (2019) Tyrosine Kinase Inhibitors
Available for Chronic Myeloid Leukemia: Efficacy and Safety. Front Oncol 9, 603
Zhang, J., Adrian, F. J., Jahnke, W., Cowan-Jacob, S. W., Li, A. G., Iacob, R. E., Sim, T.,
Powers, J., Dierks, C., Sun, F., Guo, G. R., Ding, Q., Okram, B., Choi, Y., Wojciechowski, A.,
Deng, X., Liu, G., Fendrich, G., Strauss, A., Vajpai, N., Grzesiek, S., Tuntland, T., Liu, Y.,
Bursulaya, B., Azam, M., Manley, P. W., Engen, J. R., Daley, G. Q., Warmuth, M., and
Gray, N. S. (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site
inhibitors. Nature 463, 501-506
Ha, B. H., Simpson, M. A., Koleske, A. J., and Boggon, T. J. (2015) Structure of the
ABL2/ARG kinase in complex with dasatinib. Acta Crystallogr F Struct Biol Commun 71,
443-448
Nagar, B., Bornmann, W. G., Pellicena, P., Schindler, T., Veach, D. R., Miller, W. T.,
Clarkson, B., and Kuriyan, J. (2002) Crystal structures of the kinase domain of c-Abl in
complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res
62, 4236-4243
Harrison, S. C. (2003) Variation on an Src-like theme. Cell 112, 737-740
Roskoski, R., Jr. (2005) Src kinase regulation by phosphorylation and dephosphorylation.
Biochem Biophys Res Commun 331, 1-14
Engen, J. R., Wales, T. E., Hochrein, J. M., Meyn, M. A., 3rd, Banu Ozkan, S., Bahar, I., and
Smithgall, T. E. (2008) Structure and dynamic regulation of Src-family kinases. Cell Mol
Life Sci 65, 3058-3073
Hantschel, O., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K., Kuriyan, J., and SupertiFurga, G. (2003) A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112, 845-857
Arias-Salgado, E. G., Lizano, S., Sarkar, S., Brugge, J. S., Ginsberg, M. H., and Shattil, S. J.
(2003) Src kinase activation by direct interaction with the integrin beta cytoplasmic
domain. Proc Natl Acad Sci U S A 100, 13298-13302
Franz, W. M., Berger, P., and Wang, J. Y. (1989) Deletion of an N-terminal regulatory
domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J 8, 137-147
Nagar, B., Hantschel, O., Seeliger, M., Davies, J. M., Weiss, W. I., Superti-Furga, G., and
Kuriyan, J. (2006) Organization of the SH3-SH2 unit in active and inactive forms of the cAbl tyrosine kinase. Mol Cell 21, 787-798
Panjarian, S., Iacob, R. E., Chen, S., Engen, J. R., and Smithgall, T. E. (2013) Structure and
dynamic regulation of Abl kinases. The Journal of biological chemistry 288, 5443-5450
Chen, S., Brier, S., Smithgall, T. E., and Engen, J. R. (2007) The Abl SH2-kinase linker
naturally adopts a conformation competent for SH3 domain binding. Protein Sci 16, 572581
Majidi, M., Hubbs, A. E., and Lichy, J. H. (1998) Activation of extracellular signalregulated kinase 2 by a novel Abl-binding protein, ST5. J Biol Chem 273, 16608-16614
Dai, Z., and Pendergast, A. M. (1995) Abi-2, a novel SH3-containing protein interacts
with the c-Abl tyrosine kinase and modulates c-Abl transforming activity. Genes Dev 9,
2569-2582
94

76.

77.

78.

79.

80.

81.

82.

83.

84.
85.

86.

87.
88.

89.
90.
91.

Lamontanara, A. J., Georgeon, S., Tria, G., Svergun, D. I., and Hantschel, O. (2014) The
SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling
activation loop accessibility. Nat Commun 5, 5470
Filippakopoulos, P., Kofler, M., Hantschel, O., Gish, G. D., Grebien, F., Salah, E.,
Neudecker, P., Kay, L. E., Turk, B. E., Superti-Furga, G., Pawson, T., and Knapp, S. (2008)
Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and
kinase activation. Cell 134, 793-803
Grebien, F., Hantschel, O., Wojcik, J., Kaupe, I., Kovacic, B., Wyrzucki, A. M., Gish, G. D.,
Cerny-Reiterer, S., Koide, A., Beug, H., Pawson, T., Valent, P., Koide, S., and SupertiFurga, G. (2011) Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
Cell 147, 306-319
Dorey, K., Engen, J. R., Kretzschmar, J., Wilm, M., Neubauer, G., Schindler, T., and
Superti-Furga, G. (2001) Phosphorylation and structure-based functional studies reveal a
positive and a negative role for the activation loop of the c-Abl tyrosine kinase.
Oncogene 20, 8075-8084
Chen, S., O'Reilly, L. P., Smithgall, T. E., and Engen, J. R. (2008) Tyrosine phosphorylation
in the SH3 domain disrupts negative regulatory interactions within the c-Abl kinase core.
J Mol Biol 383, 414-423
Merő, B., Radnai, L., Gógl, G., Tőke, O., Leveles, I., Koprivanacz, K., Szeder, B., Dülk, M.,
Kudlik, G., Vas, V., Cserkaszky, A., Sipeki, S., Nyitray, L., Vértessy, B. G., and Buday, L.
(2019) Structural insights into the tyrosine phosphorylation-mediated inhibition of SH3
domain-ligand interactions. The Journal of biological chemistry 294, 4608-4620
Steen, H., Fernandez, M., Ghaffari, S., Pandey, A., and Mann, M. (2003) Phosphotyrosine
Mapping in Bcr/Abl Oncoprotein Using Phosphotyrosine-specific Immonium Ion
Scanning*. Molecular & Cellular Proteomics 2, 138-145
Salomon, A. R., Ficarro, S. B., Brill, L. M., Brinker, A., Phung, Q. T., Ericson, C., Sauer, K.,
Brock, A., Horn, D. M., Schultz, P. G., and Peters, E. C. (2003) Profiling of tyrosine
phosphorylation pathways in human cells using mass spectrometry. Proceedings of the
National Academy of Sciences 100, 443-448
Hantschel, O., and Superti-Furga, G. (2004) Regulation of the c-Abl and Bcr-Abl tyrosine
kinases. Nat Rev Mol Cell Biol 5, 33-44
Plattner, R., Kadlec, L., DeMali, K. A., Kazlauskas, A., and Pendergast, A. M. (1999) c-Abl
is activated by growth factors and Src family kinases and has a role in the cellular
response to PDGF. Gene Dev 13, 2400-2411
Plattner, R., Irvin, B. J., Guo, S. L., Blackburn, K., Kazlauskas, A., Abraham, R. T., York, J.
D., and Pendergast, A. M. (2003) A new link between the c-Abl tyrosine kinase and
phosphoinositide signalling through PLC-gamma 1. Nat Cell Biol 5, 309-319
Srinivasan, D., Kaetzel, D. M., and Plattner, R. (2009) Reciprocal regulation of Abl and
receptor tyrosine kinases. Cell Signal 21, 1143-1150
Bradley, W. D., Hernandez, S. E., Settleman, J., and Koleske, A. J. (2006) Integrin
signaling through arg activates p190RhoGAP by promoting its binding to p120RasGAP
and recruitment to the membrane. Mol Biol Cell 17, 4827-4836
Shaul, Y., and Ben-Yehoyada, M. (2005) Role of c-Abl in the DNA damage stress
response. Cell Res 15, 33-35
Gu, J. J., Ryu, J. R., and Pendergast, A. M. (2009) Abl tyrosine kinases in T-cell signaling.
Immunol Rev 228, 170-183
Harburger, D. S., and Calderwood, D. A. (2009) Integrin signalling at a glance. Journal of
Cell Science 122, 159-163
95

92.

93.

94.

95.

96.

97.

98.

99.

100.

101.

102.

103.

104.
105.

106.

Lewis, J. M., Baskaran, R., Taagepera, S., Schwartz, M. A., and Wang, J. Y. (1996) Integrin
regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl
Acad Sci U S A 93, 15174-15179
Beaty, B. T., Sharma, V. P., Bravo-Cordero, J. J., Simpson, M. A., Eddy, R. J., Koleske, A. J.,
and Condeelis, J. (2013) beta1 integrin regulates Arg to promote invadopodial
maturation and matrix degradation. Mol Biol Cell 24, 1661-1675, S1661-1611
Moresco, E. M., Donaldson, S., Williamson, A., and Koleske, A. J. (2005) Integrinmediated dendrite branch maintenance requires Abelson (Abl) family kinases. J Neurosci
25, 6105-6118
Kerrisk, M. E., and Koleske, A. J. (2013) Arg kinase signaling in dendrite and synapse
stabilization pathways: Memory, cocaine sensitivity, and stress. Int J Biochem Cell B 45,
2496-2500
Omar, M. H., Kerrisk Campbell, M., Xiao, X., Zhong, Q., Brunken, W. J., Miner, J. H.,
Greer, C. A., and Koleske, A. J. (2017) CNS Neurons Deposit Laminin α5 to Stabilize
Synapses. Cell reports 21, 1281-1292
Tybulewicz, V. L. J., Crawford, C. E., Jackson, P. K., Bronson, R. T., and Mulligan, R. C.
(1991) Neonatal Lethality and Lymphopenia in Mice with a Homozygous Disruption of
the C-Abl Protooncogene. Cell 65, 1153-1163
Schwartzberg, P. L., Stall, A. M., Hardin, J. D., Bowdish, K. S., Humaran, T., Boast, S.,
Harbison, M. L., Robertson, E. J., and Goff, S. P. (1991) Mice Homozygous for the Ablm1
Mutation Show Poor Viability and Depletion of Selected B-Cell and T-Cell Populations.
Cell 65, 1165-1175
Zipfel, P. A., Grove, M., Blackburn, K., Fujimoto, M., Tedder, T. F., and Pendergast, A. M.
(2000) The c-Abl tyrosine kinase is regulated downstream of the B cell antigen receptor
and interacts with CD19. J Immunol 165, 6872-6879
Gil-Henn, H., Patsialou, A., Wang, Y., Warren, M. S., Condeelis, J. S., and Koleske, A. J.
(2013) Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo.
Oncogene 32, 2622-2630
Weigel, M. T., Banerjee, S., Arnedos, M., Salter, J., A'Hern, R., Dowsett, M., and Martin,
L. A. (2013) Enhanced expression of the PDGFR/Abl signaling pathway in aromatase
inhibitor-resistant breast cancer. Ann Oncol 24, 126-133
Oxley, C. L., Anthis, N. J., Lowe, E. D., Vakonakis, I., Campbell, I. D., and Wegener, K. L.
(2008) An integrin phosphorylation switch: the effect of beta3 integrin tail
phosphorylation on Dok1 and talin binding. J Biol Chem 283, 5420-5426
Anthis, N. J., Haling, J. R., Oxley, C. L., Memo, M., Wegener, K. L., Lim, C. J., Ginsberg, M.
H., and Campbell, I. D. (2009) Beta integrin tyrosine phosphorylation is a conserved
mechanism for regulating talin-induced integrin activation. J Biol Chem 284, 3670036710
MacGrath, S. M., and Koleske, A. J. (2012) Arg/Abl2 modulates the affinity and
stoichiometry of binding of cortactin to F-actin. Biochemistry 51, 6644-6653
Leung, K. K., Hause, R. J., Jr., Barkinge, J. L., Ciaccio, M. F., Chuu, C.-P., and Jones, R. B.
(2014) Enhanced prediction of Src homology 2 (SH2) domain binding potentials using a
fluorescence polarization-derived c-Met, c-Kit, ErbB, and androgen receptor
interactome. Mol Cell Proteomics 13, 1705-1723
Roumiantsev, S., Shah, N. P., Gorre, M. E., Nicoll, J., Brasher, B. B., Sawyers, C. L., and
Van Etten, R. A. (2002) Clinical resistance to the kinase inhibitor STI-571 in chronic
myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl
Acad Sci U S A 99, 10700-10705
96

107.
108.
109.

110.
111.
112.

113.

114.

115.

116.

117.
118.

119.

120.

121.

122.

123.

Azam, M., Latek, R. R., and Daley, G. Q. (2003) Mechanisms of autoinhibition and STI571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112, 831-843
Calderwood, D. A. (2004) Integrin activation. J Cell Sci 117, 657-666
Woodard, A. S., Garcia-Cardena, G., Leong, M., Madri, J. A., Sessa, W. C., and Languino,
L. R. (1998) The synergistic activity of alphavbeta3 integrin and PDGF receptor increases
cell migration. J Cell Sci 111 ( Pt 4), 469-478
Eliceiri, B. P. (2001) Integrin and growth factor receptor crosstalk. Circ Res 89, 1104-1110
Schwartz, M. A., and Ginsberg, M. H. (2002) Networks and crosstalk: integrin signalling
spreads. Nat Cell Biol 4, E65-68
Edick, M. J., Tesfay, L., Lamb, L. E., Knudsen, B. S., and Miranti, C. K. (2007) Inhibition of
integrin-mediated crosstalk with epidermal growth factor receptor/Erk or Src signaling
pathways in autophagic prostate epithelial cells induces caspase-independent death.
Mol Biol Cell 18, 2481-2490
Takada, Y., Takada, Y. K., and Fujita, M. (2017) Crosstalk between insulin-like growth
factor (IGF) receptor and integrins through direct integrin binding to IGF1. Cytokine
Growth Factor Rev 34, 67-72
Zemskov, E. A., Loukinova, E., Mikhailenko, I., Coleman, R. A., Strickland, D. K., and
Belkin, A. M. (2009) Regulation of platelet-derived growth factor receptor function by
integrin-associated cell surface transglutaminase. J Biol Chem 284, 16693-16703
Warren, M. S., Bradley, W. D., Gourley, S. L., Lin, Y. C., Simpson, M. A., Reichardt, L. F.,
Greer, C. A., Taylor, J. R., and Koleske, A. J. (2012) Integrin beta 1 Signals through Arg to
Regulate Postnatal Dendritic Arborization, Synapse Density, and Behavior. Journal of
Neuroscience 32, 2824-2834
Tadokoro, S., Shattil, S. J., Eto, K., Tai, V., Liddington, R. C., de Pereda, J. M., Ginsberg, M.
H., and Calderwood, D. A. (2003) Talin binding to integrin beta tails: a final common step
in integrin activation. Science 302, 103-106
Morse, E. M., Brahme, N. N., and Calderwood, D. A. (2014) Integrin cytoplasmic tail
interactions. Biochemistry 53, 810-820
Garcia-Alvarez, B., de Pereda, J. M., Calderwood, D. A., Ulmer, T. S., Critchley, D.,
Campbell, I. D., Ginsberg, M. H., and Liddington, R. C. (2003) Structural determinants of
integrin recognition by talin. Mol Cell 11, 49-58
Wegener, K. L., Partridge, A. W., Han, J., Pickford, A. R., Liddington, R. C., Ginsberg, M.
H., and Campbell, I. D. (2007) Structural basis of integrin activation by talin. Cell 128,
171-182
Goksoy, E., Ma, Y. Q., Wang, X., Kong, X., Perera, D., Plow, E. F., and Qin, J. (2008)
Structural basis for the autoinhibition of talin in regulating integrin activation. Mol Cell
31, 124-133
Anthis, N. J., Wegener, K. L., Ye, F., Kim, C., Goult, B. T., Lowe, E. D., Vakonakis, I., Bate,
N., Critchley, D. R., Ginsberg, M. H., and Campbell, I. D. (2009) The structure of an
integrin/talin complex reveals the basis of inside-out signal transduction. EMBO J 28,
3623-3632
Liu, W., Draheim, K. M., Zhang, R., Calderwood, D. A., and Boggon, T. J. (2013)
Mechanism for KRIT1 release of ICAP1-mediated suppression of integrin activation. Mol
Cell 49, 719-729
Draheim, K. M., Huet-Calderwood, C., Simon, B., and Calderwood, D. A. (2017) Nuclear
Localization of Integrin Cytoplasmic Domain-associated Protein-1 (ICAP1) Influences
beta1 Integrin Activation and Recruits Krev/Interaction Trapped-1 (KRIT1) to the
Nucleus. J Biol Chem 292, 1884-1898
97

124.

125.

126.
127.
128.
129.

130.

131.

132.

133.

134.
135.
136.
137.

138.

139.

140.

Rantala, J. K., Pouwels, J., Pellinen, T., Veltel, S., Laasola, P., Mattila, E., Potter, C. S.,
Duffy, T., Sundberg, J. P., Kallioniemi, O., Askari, J. A., Humphries, M. J., Parsons, M.,
Salmi, M., and Ivaska, J. (2011) SHARPIN is an endogenous inhibitor of β1-integrin
activation. Nat Cell Biol 13, 1315-1324
Kiema, T., Lad, Y., Jiang, P., Oxley, C. L., Baldassarre, M., Wegener, K. L., Campbell, I. D.,
Ylanne, J., and Calderwood, D. A. (2006) The molecular basis of filamin binding to
integrins and competition with talin. Mol Cell 21, 337-347
Legate, K. R., and Fässler, R. (2009) Mechanisms that regulate adaptor binding to βintegrin cytoplasmic tails. Journal of Cell Science 122, 187-198
Liu, J., Das, M., Yang, J., Ithychanda, S. S., Yakubenko, V. P., Plow, E. F., and Qin, J. (2015)
Structural mechanism of integrin inactivation by filamin. Nat Struct Mol Biol 22, 383-389
Bouvard, D., Pouwels, J., De Franceschi, N., and Ivaska, J. (2013) Integrin inactivators:
balancing cellular functions in vitro and in vivo. Nat Rev Mol Cell Biol 14, 430-442
Veevers-Lowe, J., Ball, S. G., Shuttleworth, A., and Kielty, C. M. (2011) Mesenchymal
stem cell migration is regulated by fibronectin through α5β1-integrin-mediated
activation of PDGFR-β and potentiation of growth factor signals. Journal of Cell Science
124, 1288-1300
Primac, I., Maquoi, E., Blacher, S., Heljasvaara, R., Van Deun, J., Smeland, H. Y., Canale,
A., Louis, T., Stuhr, L., Sounni, N. E., Cataldo, D., Pihlajaniemi, T., Pequeux, C., De Wever,
O., Gullberg, D., and Noel, A. (2019) Stromal integrin α11 regulates PDGFR-β signaling
and promotes breast cancer progression. J Clin Invest 129, 4609-4628
Li, H., Deng, Y., Sun, K., Yang, H., Liu, J., Wang, M., Zhang, Z., Lin, J., Wu, C., Wei, Z., and
Yu, C. (2017) Structural basis of kindlin-mediated integrin recognition and activation.
Proc Natl Acad Sci U S A 114, 9349-9354
Mould, A. P., Akiyama, S. K., and Humphries, M. J. (1995) Regulation of integrin alpha 5
beta 1-fibronectin interactions by divalent cations. Evidence for distinct classes of
binding sites for Mn2+, Mg2+, and Ca2+. J Biol Chem 270, 26270-26277
Bouaouina, M., Lad, Y., and Calderwood, D. A. (2008) The N-terminal domains of talin
cooperate with the phosphotyrosine binding-like domain to activate beta1 and beta3
integrins. J Biol Chem 283, 6118-6125
Soung, Y. H., Clifford, J. L., and Chung, J. (2010) Crosstalk between integrin and receptor
tyrosine kinase signaling in breast carcinoma progression. Bmb Rep 43, 311-318
Somanath, P. R., Malinin, N. L., and Byzova, T. V. (2009) Cooperation between integrin
alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis 12, 177-185
Ivaska, J., and Heino, J. (2011) Cooperation Between Integrins and Growth Factor
Receptors in Signaling and Endocytosis. Annu Rev Cell Dev Bi 27, 291-320
Meves, A., Geiger, T., Zanivan, S., DiGiovanni, J., Mann, M., and Fässler, R. (2011) β1
integrin cytoplasmic tyrosines promote skin tumorigenesis independent of their
phosphorylation. Proceedings of the National Academy of Sciences 108, 15213
Meves, A., Stremmel, C., Bottcher, R. T., and Fassler, R. (2013) beta1 integrins with
individually disrupted cytoplasmic NPxY motifs are embryonic lethal but partially active
in the epidermis. J Invest Dermatol 133, 2722-2731
Calderwood, D. A., Yan, B., de Pereda, J. M., Alvarez, B. G., Fujioka, Y., Liddington, R. C.,
and Ginsberg, M. H. (2002) The phosphotyrosine binding-like domain of talin activates
integrins. J Biol Chem 277, 21749-21758
Anthis, N. J., Wegener, K. L., Critchley, D. R., and Campbell, I. D. (2010) Structural
diversity in integrin/talin interactions. Structure 18, 1654-1666

98

141.

142.

143.

144.

145.
146.

Chiarugi, P., Cirri, P., Taddei, M. L., Talini, D., Doria, L., Fiaschi, T., Buricchi, F., Giannoni,
E., Camici, G., Raugei, G., and Ramponi, G. (2002) New perspectives in PDGF receptor
downregulation: the main role of phosphotyrosine phosphatases. J Cell Sci 115, 22192232
Lennartsson, J., Wardega, P., Engstrom, U., Hellman, U., and Heldin, C. H. (2006) Alix
facilitates the interaction between c-Cbl and platelet-derived growth factor betareceptor and thereby modulates receptor down-regulation. J Biol Chem 281, 3915239158
Cao, C., Li, Y. P., Leng, Y. M., Li, P., Ma, Q. J., and Kufe, D. (2005) Ubiquitination and
degradation of the Arg tyrosine kinase is regulated by oxidative stress. Oncogene 24,
2433-2440
Choudhury, G. G., Biswas, P., Grandaliano, G., Fouqueray, B., Harvey, S. A., and Abboud,
H. E. (1994) PDGF-mediated activation of phosphatidylinositol 3 kinase in human
mesangial cells. Kidney Int 46, 37-47
Schneider, C. A., Rasband, W. S., and Eliceiri, K. W. (2012) NIH Image to ImageJ: 25 years
of image analysis. Nat Methods 9, 671-675
Parsons, M., Messent, A. J., Humphries, J. D., Deakin, N. O., and Humphries, M. J. (2008)
Quantification of integrin receptor agonism by fluorescence lifetime imaging. J Cell Sci
121, 265-271

.

99

ProQuest Number: 28322273
INFORMATION TO ALL USERS
The quality and completeness of this reproduction is dependent on the quality
and completeness of the copy made available to ProQuest.

Distributed by ProQuest LLC ( 2021 ).
Copyright of the Dissertation is held by the Author unless otherwise noted.

This work may be used in accordance with the terms of the Creative Commons license
or other rights statement, as indicated in the copyright statement or in the metadata
associated with this work. Unless otherwise specified in the copyright statement
or the metadata, all rights are reserved by the copyright holder.

This work is protected against unauthorized copying under Title 17,
United States Code and other applicable copyright laws.

Microform Edition where available © ProQuest LLC. No reproduction or digitization
of the Microform Edition is authorized without permission of ProQuest LLC.

ProQuest LLC
789 East Eisenhower Parkway
P.O. Box 1346
Ann Arbor, MI 48106 - 1346 USA

